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Chapter I 
ROLE OF LAPAROTOMY AND SPLENECTOMY IN THE MANAGEMENT 
OF HODGKIN'S DISEASE 
It is now generally accepted, that patients with a localized form 
of Hodgkin's disease can be cured by radiotherapy (1-7). 
Recent publications also indicate, that there is a chance of cure 
in the more disseminated forms of Hodgkin's disease, treated with 
extensive chemotherapy (8-11). 
There is also little doubt that the first treatment offers the pa-
tient the best chance for cure(12). The choice of the initial treat-
ment is therefore of utmost importance. Since the choice of treatment 
depends on the extent of the disease, it is necessary to assess the 
localization as accurate as possible at the first admission. 
Explorative laparotomy with splenectomy was therefore introduced 
by Glatstein et al.(13),initially on a selective basis in patients 
with Hodgkin's disease. 
Later, a more systematic study of the value of routine laparotomy 
with splenectomy and biopsies in a series of unselected cases of 
untreated patients with Hodgkin's disease was published (14). A 
remarkably high yield of clinically unsuspected positive findings 
in the spleen, and to a lesser extent in the lymph nodes and the 
liver was found. 
Since that time several other centres have carried out this pro-
cedure and confirmed the findings of these initial studies. 
Exploratory laparotomy with splenectomy procedure 
The technique of laparotomy with splenectomy in our institute 
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employs in most cases a long transverse subcostal incision. In some 
patients a long left paramedian incision is made. Some surgeons 
in other centres favour a vertical mid-line approach, while others 
prefer an extended left subcostal incision (15). 
Following careful inspection,the spleen is removed with its hilar 
nodes, and the splenic pedicle is marked with metal clips. 
Then a thorough systematic inspection and palpation of the abdo-
minal viscera and lymph node stations is carried out with removal 
of all suspicious lymph nodes and nodes from the hilar region of 
the liver, leaving markers. Reference is made during the operation 
to the preoperative lymphogram. It is helpful to take an opera-
tive film after placing markers if difficulty is encountered in 
identifying nodes, which appear to be involved on the lymphogram. 
A wedge liver biopsy is taken, and several deep needle biopsies 
at random and when suspect areas were visible from these regions. 
Finally an open bone marrow biopsy is taken from the iliac crest. 
Spleen 
The clinical methods currently used for assessment of the likeli-
hood of splenic involvement are physical examination. X-rays and 
radio-isotope scanning. Since exploratory laparotomy with splenec-
tomy is in use, much is learned about the accuracy of these methods. 
The results of various studies (13,16-26) about pre- and postopera-
tive evaluation of involvement of the spleen are summarized in 
Table 1. 
As is shown the overall accuracy does not differ much between the 
different methods. 
However, there are great differences in results of the various stud-
ies which used scanning as screening method. Comparing these stud-
ies is difficult because the criteria used are not always stated. 
The most used criterion is the size. This is possibly the reason 
that the results of palpation and scanning did not differ much. 
There is a certain relation between weight, size and palpation. 
H0st et al.(27) found in his series of 80 patients with Hodgkin's dis 
ease fair correlation between the spleen size as estimated by scan-
ning and the weight of the operation specimen in 90%. In all patients 
with a spleen weighing more than 300g, the preoperative scanning 
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Table 1. Comparison of C l i n i c a l E v a l u a t i o n w i t h H i s t o l o g y of Spleen 
Published Clinical evaluation 
series Histology 
I Jelliffe 
Enright 
Aiserberg 
Hass 
Prosnitz 
Rozman 
II GlatstPin 
Rosenberg 
III Jelliffe 
Mitchell 
Silvennan 
Ferguson 
Rozman 
IV Hass 
V Meeker 
1970 
1970 
1971 
1971 
1972 
1973 
1969 
1971 
1970 
1972 
1972 
1973 
1973 
1971 
1972 
Total 
4 
12 
6 
6 
2 
13 
(43) 
38 
16 
(54) 
6 
24 
5 
19 
4 
(58) 
12 
10 
177 
+ 
4 
8 
4 
6 
1 
10 
77% 
24 
8 
59% 
1 
11 
5 
14 
3 
59% 
11 
7 
117 
+ 
-
0 
4 
2 
0 
1 
3 
23% 
14 
8 
41% 
5 
13 
0 
5 
1 
41% 
1 
3 
60 
(34%) 
18 
56 
19 
44 
38 
43 
(218) 
27 
84 
(111) 
12 
20 
37 
57 
15 
(141) 
38 
18 
526 
+ 
8 
18 
9 
19 
14 
17 
39% 
16 
20 
32% 
7 
6 
15 
11 
9 
34% 
14 
8 
191 
(36%) 
_ 
-
10 
38 
10 
25 
24 
26 
61% 
11 
64 
68% 
5 
14 
22 
46 
6 
66% 
24 
10 -
335 
Methods 
used 
palpation 
(palpable 
spleen 
considered 
positive) 
palpation + radio­
logical examinaHon 
criteria : 
s c a n
 not stated 
size 
size or 
ч
 filling defects 
not stated 
not stated 
palpation + scan 
'palpation + scan+ 
radiological ex­
amination 
Estimated accuracy of 
clinical evaluation 66% 64% 
had shown enlargement. Space occupying lesions were evident in 15 
cases and were only detected in patients with positive spleen 
histology. 
Plain radiographic examination of the abdomen failed to show an 
enlarged spleen in 11 of 16 patients with spleens weighing more 
than 300 g (range 310-930). 
42 of the 80 patients had histological involvement of the spleen. 
The gross changes varied from a single minute focus to large con­
fluent tumours involving the entire spleen. Spleens weighing over 
500 g in his series were always diseased. There are, however, some 
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reports (19,23,25) about spleens weighing over 500 g with a nega-
tive pathology. Also in our institute we experienced spleens 
weighing up to 580 g without Hodgkin's disease involvement. 
On the other hand, a normal weight did not exclude splenic invol-
vement, because 11 of the 42 positive spleens of the series of H0st, 
weighed less than 200 g. 
From the table it is evident that with clinical evaluations there 
are about 35 percent false positive and false negative reports. 
The accuracy of clinical evaluation is about 6 5%. 
From the above, it can be concluded that at the present time, the 
only way to confirm the presence or absence of Hodgkin's disease 
involvement is by histological examination of the removed organ. 
What is the importance of involvement of the spleen9 
Since the spleen has no afferent lymphatics, Hodgkin's disease 
probably reaches it via the blood-stream.Smithers hypothesis (28) 
that spread of Hodgkin's disease to this organ could occur by cir-
culating blood seems therefore logical. However, retrograde spread 
from abdominal lymph nodes via efferent splenic lymph vessels as 
proposed by Rosenberg-Kaplan (29-31) cannot be excluded. 
Recent reports (32,3 3) have suggested that involvement of the 
spleen indicates hematogeneous dissemination of disease and that 
irradiation to lymph nodes is not likely to be curative, unless 
systemic chemotherapy is added. Shipley et al. (34) analysed the 
survival of stage II and stage III patients in their laparotomy 
group and attempted to isolate the effect of an involved spleen. 
In a group of 38 patients with Hodgkin's disease, matched for 
extent of disease, histologic type and age and sex,they found in 
approximately 30 percent of spleen positive patients a shorter 
disease free survival. The difference among the results occurred 
during the first 6 month after treatment. If a patient with a 
positive spleen showed no relapse within this time, the prognosis 
became similar to that of a patient without splenic involvement. 
Summarizing,it seems that involvement of the spleen is of impor-
tance for the prognosis. It probably has a similar connotation 
as involvement of an organ. 
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Abdominal lymph nodes 
Visualization of lymph nodes can be obtained by lymphangiography 
and lymph node scanning. Pedal lymphangiography is especially 
of value in detecting involvement of pelvic and para-aortic nodes 
up to the second lumbar vertebra. The inherent main defect of this 
procedure is that lymphography does not opacify mesenteric, celiac, 
portal and splenic hilar nodes. 
In an excellent review Gazet (15) compared the lymphographic find-
ings with histology of lymph nodes removed at laparotomy. In a 
series of 417 patients with Hodgkin's disease 176 patients had a 
positive lymphangiogram. Histopathologic examination of the re-
moved glands showed Hodgkin's involvement in 132 (75%) patients, 
negative histology in 42 (25%) and equivocal results in 2 cases. 
The estimated accuracy (75%) of the lymphographic results are in 
fact somewhat higher because of sampling error by the surgeon. 
There were 166 patients with negative lymphangiograms. At operation 
it was found 23 (13.8%) to be positive. 75 (18%) patients had an 
equivocal lymphangiogram. At operation it was found that 18 pa-
tients had positive, 55 negative nodes and 2 showed also an equiv-
ocal histology. 
Frequently the para-aortic lymph nodes are not well visualized by 
lymphography from the level of the second lumbar vertebra and 
higher. This is in fact, the region in which the surgeon may have 
difficulty in exploring without risking unacceptable morbidity. 
Ferguson et al.(25) described the results of laparotomy in 81 pa-
tients with Hodgkin's disease and the findings in lymph nodes from 
the lymphography "silent" sites. They found positive histology in 
20 out of 68 excised portal lymph nodes (29%), in 7 out of 16 celiac 
lymph nodes (43%), in 15 out of 70 splenic (21%) and in 8 out of 
68 mesenteric lymph nodes (12%). Each of these sites was involved 
in at least 10% of patients with Hodgkin's disease. This yield 
is rather high and reduces the reliability of the lymphangiograms. 
Unfortunately, most of the lymphography evaluation studies do not 
mention the percentage of positive lymph nodes in the blind corner 
of the lymphography. 
An advantage of lymphangiography is that serial follow up films, 
may give valuable data as to the progression or the recurrence of 
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Hodgkin's disease over a period of months (15). 
In addition lymphangiography is useful in radiation treatment plan-
ning. 
Lymph node scanning is another possibility of visualizing abdominal 
lymph nodes. This method is introduced in 1952 by Sage and Gozun 
(35). Kazem et al. (36) compared this technique with patients having 
lymphography and found the results of the methods to be compara-
ble. In their series of 75 patients a false positive result was 
found in four cases. They felt that since the visualization of nor-
mal nodes depended on normal physiology a false negative scan was 
unlikely. In the first 13 patients in our hospital in which a lymph 
node scanwas performed, it appeared that all the scans were positive. 
Pathologic examination of this series showed a false positive score 
of 6 (46%) cases. It is our impression that only the negative scans 
are reliable. This method is useful as alternative when lympho-
graphy is not feasible. 
Two other indirect methods which are occasionally used in detec-
ting lymphomatous involvement in the abdomen are inferior cavogra-
phy and intravenous urography. 
Inferior cavography can give more information than lymphography 
about enlargement of lymph nodes in the v. iliaca interna region, 
and in the region cranial to the second lumbar vertebra (37). 
On the intravenous urogram films enlarged lymph nodes may indent 
and displace one or both ureters. 
Unfortunately, displacement of the inferior vena cava or of an 
ureter requires a relatively marked degree of enlargement of lymph 
nodes for its demonstration and is thus a relatively insensitive 
diagnostic criterion. 
Liver 
Preoperative assessment of liver involvement is very difficult. 
At the Ann Arbor Conference (38) it was decided that clinical evi-
dence of liver involvement must include an enlarged liver and at 
least an abnormal serum alkaline phosphatase value, 2 different 
liver function test abnormalities, or an abnormal liver scan and 
one abnormal liver function test. Exploratory laparotomy with liv-
er biopsies has given us more insight in the value of these cri-
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teria. 
Results of preoperative clinical evaluation and post-operative pa­
thologic confirmation are illustrated in Table 2 (13,16,17,19, 
21-23, 26,27,39, 40) . 
Table 2. Comparison of Clinical Evaluation with Results of Open 
Liverbiopsy 
Authors 
Glatstein 
Jelliffe 
Hass 
Rosenberg 
Meeker 
Hellman 
Enright 
Mitchell 
Pozman 
H0St 
Lipton 
Roznan 
Estimated 
Clinical evaluation 
Histology 
1969 
1970 
1971 
1971 
1972 
1974 
1970 
1971 
1973 
1973 
1972 
1973 
Total 
accuracy of 
clinical evaluation 
21 
9 
16 
15 
12 
9 
(82) 
7 
11 
8 
8 
8 
(35) 
11 
135 
+ 
13 
1 
9 
1 
4 
4 
39% 
2 
7 
3 
5 
4 
54% 
7 
60 
44% 
+ 
-
8 
8 
7 
14 
8 
5 
61% 
5 
4 
5 
3 
4 
46% 
4 
75 
(56%) 
41 
12 
34 
85 
18 
85 
(275) 
61 
34 
13 
72 
34 
(153) 
38 
527 
+ 
8 
1 
4 
2 
1 
3 
7% 
3 
2 
4 
16 
0 
14% 
5 
49 
(9%) 
-
-
33 
11 
30 
83 
17 
82 
93% 
58 
32 
9 
56 
34 
86% 
33 
478 
91% 
Methods used 
palpation,llverfunctions + 
scan 
palpation, li verfunctions 
scan criteria 
not stated 
not stated 
__f space occupying 
~I lesions 
_
r
 enlargement, 
patchy uptake, 
„ focal lesions 
B.S.P.* and/or A.P.** 
*B.S.P.: bromsu'Lphale-in retention 
**Л.Р. : alkaline phosphatase 
All the three techniques mentioned in the table, namely palpation, 
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liver function tests and scanning are not used in all recorded pa-
tients. Liver function tests are not always comparable in the pub-
lished studies. In some studies is not stated how many abnormal-
ities were chosen for considering liver involvement. Despite 
these incompleteness of data we can make some general conclusions. 
The false positive results (56%) of clinical evaluation are much 
higher than the false negative ones (9%) . One have to realize 
however, that the entire liver can not be histologically studied 
as in the case of the spleen. False positive clinical evaluations 
therefore, are more difficult to prove. As shown by the results 
of Rozman,B.S.P. retention and alkaline phosphatase determination 
are poor in predicting the pathologic involvement of the liver. 
An important observation by various authors (16,18,19,21,23) is 
that liver involvement was always concomitant with spleen invol-
vement . 
Effect on staging 
Laparotomy with splenectomy resulted,as shown in Table 3 (15,16, 
18,20,21,26,27,39,41),in an elevation of the clinically determined 
staging in about 27 percent of the patients and in a reduction in 
about 9 percent. The overall change of the clinical stage was 40 
percent (range 17^-64%). 
Table 3. Preoperative versus Postoperative Stage 
Authors 
Jelliffe 
Rozman 
Aisenberg 
Prosnitz 
Meeker 
Gazet 
H0st 
Smith 
Heliman 
1970 
1971 
1971 
1972 
1972 
1973 
1973 
1973 
1974 
No of 
Patients 
22 
56 
25 
40 
26 
80 
80 
33 
114 
SI 
advanced 
9 
16 
7 
7 
14 
21 
36 
3 
15 
tage 
reduced 
5 
8 
5 
0 
2 
0 
-
6 
18 
Total 
change 
64% 
43% 
48% 
17%% 
6 2% 
2 6% 
45% 
27% 
29% 
Total 
16 
476 128(27%) 44 (9%) 
Secondary advantages of laparotomy and splenectomy 
During the laparotomy the surgeon can take an open bone marrow 
biopsy. As reported by Rosenberg (4 2) the technique of an open 
bone marrow biopsy is superior to a needle biopsy and bone marrow 
smears. The specimens obtained in this way are larger, and the 
yield of positive findings is much higher than with the other tech-
niques . 
Another advantage of laparotomy and splenectomy is, that silver 
cliptagging of node areas aids radiation beam localization. 
In the absence of laparotomy spleen irradiation may be necessary. 
The radiotherapy fieüs which are required to encompass the spleen 
includes some of the left lower lung and pleura and portions of 
the left kidney. There will be even more inclusion of the kidney 
when the spleen is large. When the radiotherapist can limit his 
fields to include only the identified splenic pedicle, radiation 
pneumonitis and pleuritis of the left lung base can be eliminated 
and radiation damage to the kidney can be minimized(43). 
A minor but important reason for staging laparotomy in women of 
child bearing age is the possibility of ovarian transposition away 
from the irradiation beam. 
Other advantage for splenectomy in patients with Hodgkin's disease 
are the indications that it results in improved hematologic toler-
ance during irradiation (44), and also improved tolerance to 
myelosuppressive chemotherapy (45-47). 
Mortality and morbidity 
In his review O'Brien et al.(48) collected from literature mortality 
figures on a series of staging laparotomies with splenectomies from 466 
patients which showed seven deaths. Desser and Ultmann (49) found in 
their collected series of 834 patients»death due to operation in 
6 cases. We collected from literature (15,17,19,21,25,27,41,50) an-
other 4 50 patients with Hodgkin's disease who underwent laparoto-
my with splenectomy,in which death occurred in 4 patients. In this 
collected patient material from 1750 patients the operative mortal-
ity was less than 1 percent. 
Besides the postoperative mortality rate there is the specific 
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problem of the increased susceptibility for infection after splen-
ectomy , especially overwhelming infection as a late complication 
of splenectomy. As pointed out in Chapter V this problem is not 
settled at this moment for patients with Hodgkin's disease who un-
derwent splenectomy for staging purposes. 
Other morbidity from this procedure include wound dehiscence and 
infections, subphrenic abscess, pancreatitis, inadvertent ureteral 
damage and other minor operative and postoperative complications. 
In all published series to our knowledge, the morbidity is reported 
as low. 
Conclusion 
The failure rate of clinical evaluation for detecting localization 
of Hodgkin's disease in the abdomen is high. Laparotomy with splen-
ectomy make more accurate assessment possible. The knowledge of 
the exact extent of the disease is essential for treatment plan-
ning, because the initial choice of treatment influences the 
prognosis to a great extent. 
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Chapter II 
OUTLINE OF INVESTIGATIONS AND 
OBJECTIVES IN THIS THESIS 
As pointed out in the previous chapter the major value of the lapa-
rotomy and splenectomy is a more accurate assessment of involvement 
of Hodgkin's disease in the abdomen. It has been presumed that a 
greater accuracy in determining the extent of disease might result 
in better selection and planning of the effective therapeutic meas-
urements now available. 
The influence of the splenectomy per se on the subsequent behav-
iour of Hodgkin's disease is not known at this moment. It is con-
ceivable that splenectomy could have a favourable or unfavourable 
effect on immunologic potency and therefore, exert a benificial 
or an untoward influence on the course and prognosis of Hodgkin's 
disease. This is the reason, why we started a study of the influ-
ence of splenectomy on immunity. In tumor immunology the cell 
mediated immunity is thought to be the most important (1-4). The 
main part of this study is therefore concerned with the cellular 
immunity evaluated before and after surgery (chapter III and IV). 
In addition the effect of splenectomy on humoral immunity was 
measured (chapter V) . These data are discussed in the light of 
possible increased infection rate after splenectomy in general, 
and in Hodgkin's disease in particular. 
In collecting the data from the humoral parameters, we cane across 
two interesting findings not directly related with splenectomy. 
We got the impression that whole complement levels were correlated 
with staging. We therefore extended the determination of whole 
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complement levels to all our patient material in stock and tried 
to correlate whole complement levels and some other biological 
signs (E.S.R., fibrinogen level, a2-globulin concentration, leuco-
cyte and lymphocyte count) with staging and histology. The results 
are reported in chapter VI. 
An other striking finding was the observation in many Hodgkin's 
patients of an increased IgA level. This was contrary to the study 
of Goldman (5), the only study to our knowledge about this subject. 
He reported a normal or decreased IgA level. This was the reason, 
why we enlarged the study of immunoglobulin levels to all our pa-
tients of the last 3 years. The results are described in chapter 
VII. 
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ABSTRACT 
14 Using tissue culture techniques, the C-thymidine incorporation 
of peripheral lymphocytes in 17 Hodgkin's patients was tested be-
fore and after splenectomy under stimulation with phytohemaggluti-
nin and pokeweed. 
Incorporation under phytohemagglutinin stimulation about 10 days 
after splenectomy was not affected in Hodgkin's patients with path-
ologic stages I and II, but was significantly (p <0.005) in-
creased in those with stages III and IV. The total PHA stimu-
lation potency, i.e. the product of the lymphocyte count and PHA 
stimulation, increased slightly in both groups. 
Incorporation under pokeweed stimulation after splenectomy did not 
significantly differ from that before the operation in the two 
groups. 
Although the number of cases studied is rather small, it is con-
cluded that splenectomy causes no demonstrable untoward effect on 
the cellular immunologic potency. The immunologic state is more 
likely to be favourably influenced than unfavourably. 
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INTRODUCTION 
Exploratory laparotomy and splenectomy is increasingly accepted 
as a diagnostic approach to determine the extent of Hodgkin's dis-
ease. The principal advantage of this procedure is the possibil-
ity of accurate assessment of involvement of the spleen. Secon-
dary advantages of the procedure include supplementary informa-
tion on the state of abdominal lymph nodes and facilitation of 
programs of radiotherapy and possibly also of chemotherapy (14) . 
So far there have been no publications on the influence of this 
procedure on the immunologic status. It is conceivable that splen-
ectomy could have a favourable or an unfavourable effect on immu-
nologic potency and, therefore, exert a beneficial or an untoward 
influence on the course and prognosis of Hodgkin's disease. 
This communication describes a study of some parameters of cellu-
lar immunity in patients with Hodgkin's disease, before ^nd after 
splenectomy. The parameters studied were: Phytohämagglutinin (PHA) 
stimulation as characteristic of thymus-dependent (T) lymphocytes 
(4,13) and pokeweed mitogen (PWM) stimulation as a parameter of 
bursa equivalent-dependent (B) lymphocytes as well as Τ lympho­
cytes (5,9) . 
PATIENTS AND METHODS 
Patients 
Seventeen newly admitted,untreated Hodgkin's patients were examined. 
The histologic classification used was that of the Rye Conference 
modification of the Lukes-Butler classification (10). Patients 
were classified according to clinical stage and pathologic stage, 
as described at the Ann Arbor Conference (3). The summary of pa­
tients' data and the weights of the resected spleens are presented 
in Table 1. 
Methods 
Blood samples for a lymphocyte count were obtained on 3 consecu­
tive days before and after the operation (about the 9th to 11th 
day). In addition, a single blood sample was obtained between the 
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Table 1. Summary of Patients' Data 
Patient 
1. A.H. 
2. D.L.-S. 
3. B.H.-U. 
4. G.B. 
5. R.D. 
6. M.J.-V. 
7. M.L.-H. 
8. J.V.O. 
9. M.R.-J. 
10.J.V. 
ll.W.D. 
12.A.v.d.K. 
13.E.L. 
14.A.V.W. 
IS.R.v.d.B. 
16.P.G.-B. 
17.G.H. 
Sex 
M 
Ρ 
F 
F 
M 
F 
F 
M 
F 
F 
M 
M 
M 
M 
F 
F 
M 
Age 
26 
34 
28 
26 
18 
44 
22 
42 
24 
20 
17 
30 
60 
34 
18 
40 
26 
Clinical 
staging 
I A 
I A 
I В 
U I A 
H I B 
II А 
II А 
II А 
ІІІА 
U I A 
U I A 
U I A 
U I A 
IV В 
H I B 
H I B 
IV В 
Pa­
s' 
I 
I 
I 
II 
II 
II 
II 
II 
II 
II 
thologic 
taging* 
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
IIIH-S-N+M-
IIIH-S+N+M-
IIIH-S-N+M-
IIIH-S+N+M-
IIIH-S+N-M-
IIIH-S-N+M-
IV H+S+N-M-
Histologic 
typet 
M.C. 
N.S. 
L.P. 
N.S. 
M . С 
M.C. 
N.S. 
L.P. 
M . С 
L.P. 
L.P. 
M . С 
L.D. 
M . С 
M.C. 
M.C. 
M.C. 
Spleen 
weight (g) 
230 
rather small 
290 
360 
420 
275 
330 
80 
160 
140 
530 
230 
140 
543 
460 
480 
270 
*H+ or H- for liver positive or negative ; S+ or S- for spleen pos­
itive or negative ; N+ or N~ for lymph node positive or negative ; 
M+ or M- for marrow positive or negative. 
fN.S.= nodular s olerosing, L.P.= lymphocyte predominance, M.C.= 
mixed cellularity, L.D.= lymphocyte depletion. 
7th and 1st preoperative and the 9th and 11th postoperative day, 
to start a lymphocyte culture with phytohemagglutinin (PHA) and 
pokeweed mitogen (PWM) as stimulants. 
The lymphocyte culture was carried out by a modification (2) of 
the technique described by Schellekens et al.(15). Lymphocytes were 
separated from the defibrinated blood by Ficoll-Isopaque gradient 
centrifugation. The cells were washed and resuspended in Minimum 
Essential Medium (M.E.M.-S Gibco, New York), buffered with Tris 
(0.025M),pH 7.4. The cells were counted electronically (model В 
Coulter Counter). Fresh inactivated human AB serum was added, up 
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to an end concentration of 20%. AB serum from the same donor was 
used before and after splenectomy. The medium contained penicillin 
(100 lU/ml) and streptomycin (100 yg/ml). The cell concentration 
was brought to 0.3x10 lymphocytes/ml. Samples of 1 ml were cultured 
at 370C in polystyrene vials (Nunc 70 χ 11 mm, Roskilde, Denmark). 
The PHA and PWM reactivities were determined by adding 5 0 \ig 
phytohemagglutinin (Wellcome MR 10, Beckenham, England) or 25 цд 
pokeweed mitogen (Gibco, New York) to 1 ml lymphocyte suspension. 
The cultures to which PHA had been added were terminated after 3 
culture days. The PWM-stimulated cultures were harvested on the 6th 
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culture day. To determine DNA synthesis, 2- C-thymidine (0.075pCi, 
specific activity 6.25 mCi/mmole, Amersham, England) was added 24 
hours before the cultures were terminated. In harvesting, the cells 
were collected and eluted on 0.45 \i glass-fiber filters (Millipore 
Corp., Bedford, MA), which were then dried. The filters were count­
ed for 10 minutes (Mark II, Nuclear, Chicago) in 2 ml scintilla­
tion fluid (15 g PPO and 1 g POPOP in 2 1 toluene). All cultures 
were carried out in triplicate. The normal value with sd.of the PHA 
response was 6919 cpm + 1614 (n=34) and of the nokeweed stimulation 
4337 cpm ± 8 55 (n=31) per О.ЗхЮ6 cells. The "Total PHA Stimulation 
Potency" (TPSP) was expressed as a product of the lymphocyte 
count per μΐ venous blood in vivo and the cpm in the standardized 
PHA stimulation test. 
The postoperative stimulation potency was expressed as a percentage 
of that prior to the operation (lOOxTPSP after /TPSP before). Sta­
tistical analysis was carried out with the aid of the Student's 
t-test on the differences of paired observations. 
RESULTS 
Patients were classified according to pathologic stages and grouped 
in two groups. The first group consisted of the less extensive 
forms, stages I and II; the other group consisted of the more ex­
tensive forms, stages III and IV. 
The first column of Table 2 lists the mean lymphocyte counts for 
stages I and II before and after splenectomy, showing a slight in­
crease after the operation but no significant difference. 
The second column lists the PHA-stimulated thymidine incorporation 
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Table 2. Results of Lymphocyte Count and PHA Stimulation in Pa­
tients with Pathologic Stages I and II 
Lymphocyte PHA stimu- PHA stimu- Total PHA 
1. Α.H 
2. D.L.-S. 
3. B.H.-U. 
4. G.B. 
5. R.D. 
6. M.J.-V. 
7. M.L.-H. 
8. J.V.O. 
9. M.R.-J. 
10.J.V. 
Mean 
count 
per 
before 
1.400 
1.300 
1.400 
1.600 
2.700 
1.600 
1.300 
2.600 
2.000 
1.500 
1.700 
mm 
after 
2.800 
1.900 
1.800 
2.100 
2.500 
1.500 
1.500 
2.900 
1.700 
N.D.T 
2.100 
lation m 
CPU 
before 
5.9 29 
6.397 
5.256 
4.176 
8.915 
2.333 
8.999 
7.585 
9.962 
8.372 
6.792 
after 
5.110 
6.994 
4.607 
6.783 
8.567 
2.820 
8.494 
5.937 
1L952 
7.486 
6.875 
lation 
ratio 
(after/before) 
0.86 
1.09 
0.88 
1.62 
0.96 
1.21 
0.94 
0.78 
1.20 
0.80 
1.03 
stimu­
lation 
potency* 
173 
160 
113 
212 
89 
114 
108 
86 
101 
128.4 
*Total РИА Stimulation Potency: 
3 lymphocyte count per mm χ РИА stimulation in CPM after surgery 
2 '—' x 1 0 0 
lymphocyte count per mm χ PHA stimulation in CPU before surgery 
t N.D.- not done 
in cpm before and after the operation, showing slight to moderate 
increases (with the exception of patient 4, G.B.) as well as slight 
to moderate decreases. Per group, however, there was no significant 
difference between preoperative and postoperative values. The PHA 
ratio, i.e. the quotient of the postoperative and the preoperative 
PHA stimulation value, likewise showed no difference (column 3). 
The final column indicates the TPSP of the lymphocytes after the 
operation as a percentage of that before the operation. There 
seems to be an increase in TPSP, which is to be attributed chiefly 
to the increase in the number of lymphocytes. 
In stages III and IV (Table 3) we likewise observe a slight increase 
in the number of lymphocytes as well as a significant increase 
(p<0.005) m PHA stimulation (columns 3,4 and 5). Here too, the 
TPSP of the lymphocytes from peripheral blood seems to be increased 
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Table 3. Results of Lymphocyte Count and PHA Stimulation in Pa­
tients with Pathologic Stages III and IV 
ll.W.D. 
12.A.v.d.K. 
13.E.L. 
14.A.V.W. 
IS.R.v.d.B. 
16.P.G.-B. 
17.G.H. 
Lymph ocyte 
count 
per 
before 
2.000 
3.000 
1.300 
1.100 
2.700 
2.600 
2.600 
mm 
after 
2.000 
3.300 
1.200 
1.000 
2.700 
3.200 
3.400 
PHA stimu­
lation in 
CPM 
before 
5.160 
4.572 
5.405 
3.613 
7.863 
2.587 
4.021 
after 
7.802 
4.326 
7.201 
6.777 
9.322 
4.828 
4.913 
PHA stimu­
lation 
ratio 
(after/before) 
1.51 
0.95 
1.33 
1.88 
1.19 
1.87 
1.22 
Total PHA 
stimu­
lation 
potency* 
151 
102 
122 
171 
119 
229 
160 
Mean 2.200 2.400 4.746 6.453t 1.42 151 
*Total PHA Stimulation Potency: 
lymphocyte count per mm χ PHA stimulation in CPM after surgery 
3 lymphocyte count per mm χ PHA stimulation in CPM before surgery 
tp <0.005 by Student's t-test on paired observations 
xlOO 
mainly due to better stimulation of the lymphocytes after the 
operation. 
There was no significant difference in PHA stimulation before and 
after the operation in relation to histology, spleen weight, and 
positive or negative pathology of the spleen. 
In both groups,PWM stimulation (Tables 4 and 5) showed no signi­
ficant changes, but there seemed to be a slight increase in pa­
tients in stages III and IV. 
DISCUSSION 
Any determination of immunologic parameters immediately after splen­
ectomy is bound to be strongly influenced by the depressant effect 
of the surgical procedure as such on immunity (7,11,12). The time 
of assessment was therefore postponed as long as possible after 
the operation, but not beyond the 11th postoperative day, because 
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this was the time at which therapy was started. Such therapy, 
whether irradiation or cytostatic medication, is known to exert a 
Fig.l. The PHA Stimulation in CPM before and after Splenectomy 
c p m 
12000 -
1 0 0 0 0 -
8 0 0 0 -
6 0 0 0 -
4 0 0 0 -
2 0 0 0 -
before after before after 
depressant influence on immunity (6,16). 
The findings presented in this paper show that no depression of 
PHA stimulation of lymphocytes is generally observed in Hodgkin's 
patients about the 10th day after splenectomy. In fact the PHA 
stimulation in the more progressive forms of Hodgkin's disease 
seems to have improved. 
The "TPSP" (lymphocyte number χ cpm in the PHA stimulation test) 
also increases in the majority of patients, regardless of the 
stage. This would seem to be based chiefly on an increase in the 
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Stages 
I and II 
Stages 
III and IV 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10 
A.H. 
D.L.-S. 
В.H.-U. 
G.B. 
R.D. 
M.J.-V. 
M.L.-H. 
J.v.O. 
M.R.-J. 
.J.V. 
3814 
3586 
4172 
3316 
3943 
3006 
5858 
5620 
4151 
6307 
3795 
5439 
4227 
4065 
3977 
3814 
5618 
7084 
3677 
4107 
Table 4. Results of PWM Stimulation in Patients with Pathologic 
Stages I and II 
PWM stimulation PWM stimulation 
in CPM ratio 
before after (after/before) 
1.00 
1.52 
1.01 
1.23 
1 .01 
1.27 
0.96 
1.26 
0.89 
0.65 
Mean 4377 4580 1.08 
Table 5. Results of PWM Stimulation in Patients with Pathologic 
Stages III and IV 
PWM stimulation 
ratio 
(after/before) 
ll.W.D. 2106 3006 1.43 
12.A.v.d.K. 3620 4407 1.22 
13.E.L. 3402 3929 1.15 
14.A.V.W. 2860 4978 1.74 
IS.R.v.d.B. 2963 1305 0.44 
16.P.G.-B. 2634 3391 1.29 
17.G.H. 2525 2683 1.06 
Mean 2873 3385 1.19 
number of lymphocytes in patients with stages I and II, and on 
enhanced stimulation of the lymphocyte population in patients with 
stages III and IV. This enhanced stimulation of the lymphocyte pop­
ulation might be a result of a shift in the ratio between Τ lym-
PWM stimulation 
in 
before 
CPM 
after 
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phocytes and В lymphocytes after the operation; in other words, 
relatively more Τ lymphocytes could have entered the circulation 
after the splenectomy. Another possible explanation is that the 
enhanced stimulation is due to elimination of a "serum inhibitor", 
which Hellström demonstrated in splenectomized mice by means of 
the colony inhibition test (8). PHA tests which were carried out 
for this purpose in our patients with autologous serum,produced 
no evidence in this direction. 
To exclude the possibility that splenectomy increases the PHA sen-
sitivity of the lymphocytes, PHA dose-response curves before and 
after splenectomy are in study. 
On about the 10th postoperative day, PWM stimulation was not sig-
nificantly different from that before the operation. Patients with 
stages III and IV generally showed a slight but not significant 
increase in PWM stimulation. This is probably due to the fact, sug-
gested by some data, that the В lymphocyte response to PWM may be 
greater than that of the Τ lymphocyte (1,9,17). 
It seems therefore that about 10 days after splenectomy there is 
no demonstrable untoward effect of this operation on the cellular 
immunologic potency in so far as this is reflected in the PHA test, 
and that the immunologic state is more likely to be favourably in­
fluenced than unfavourably. To confirm our impression, further ob­
servations and studies of more patients material are necessary. 
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ABSTRACT 
Cellular immunity was evaluated in 15 untreated patients with 
Hodgkin's disease before and about 10 days after splenectomy. 
Skintest-reactivity was not.affected by the operation. 
The number of lymphocytes was moderately increased in patients 
with pathological stage I and II. 
The relative proportion of Ε-binding lymphocytes in the periph­
eral blood diminished significantly (p:0.001) in patients with 
splenic weights of 240 grams and more, whereas the PHA stimulated 
thymidine incorporation increased significantly (p:0.015) and the 
proportion of EAC-binding lymphocytes increased significantly 
(p:0.023). 
The PHA-stimulation of peripheral lymphocytes in patients with 
pathological stage I and II was at the same level before and af­
ter operation, but increased significantly (p<0.02) in the more 
disseminated forms. 
The stimulation of the lymphocytes in vitro by a cocktail of anti­
gens and by allogeneic cells (MLC) remained unchanged. 
Although the number of cases studied is rather small, it is con­
cluded that about 10 days after splenectomy, there is no demon­
strable untoward effect on the cellular immunological potency. 
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INTRODUCTION 
Explorative laparotomy with splenectomy is increasingly used as a 
diagnostic approach to determine the extent of Hodgkin's disease. 
It is conceivable that splenectomy, removal of a reservoir of lym­
phocytes, could have an unfavourable effect on the immunological 
status of the patient. 
In an earlier communication the authors (30) reported the influ­
ence of splenectomy in Hodgkin's patients on the phytohemaggluti-
nin (PHA) stimulation of peripheral lymphocytes. The reaction to 
PHA as stimulant was studied as characteristic of thymus dependent 
(T) lymphocytes (8,22). It was found that generally no depression 
of PHA stimulation of the peripheral lymphocytes occurred about 10 
days after splenectomy. PHA stimulation in the more progressive 
forms of Hodgkin's disease even appeared to have improved. It is 
possible that this increased stimulation is due to a shift in Τ 
and bursa equivalent dependent (B) lymphocytes. 
An analysis of the relative proportion of Τ and В cells, there­
fore, has been carried out in these patients, which is reported 
in this paper. Spontaneous rosette forming capacity for sheep 
red blood-cells (E), a property of human T-lymphocytes (5,14), 
and one surface marker characteristic for B-lymphocytes (recep­
tors for activated complement, EAC) (4,10) have been investigated 
before and after operation. 
In addition, the influence of splenectomy on mixed lymphocyte 
cultures (MLC) was studied, because the MLC is claimed to be 
a more relevant and probably a more sensitive assay of immunologi­
cal competence than PHA stimulation (17). 
A number of authors described a diminished delayed hypersensi­
tivity in Hodgkin's disease (1,6,11,15,16,25,27,31). This paper 
also reports the findings of skintest-reactivity before and after 
splenectomy and in vitro reactivity of lymphocytes against the 
same antigens used for skintesting to eliminate aspecific influ­
ence of peripheral lymphopenia on cellular anamnestic response (18). 
PATIENTS AND METHODS 
Patients 
15 newly admitted,untreated Hodgkin's patients were studied. The 
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histological material was examined by two pathologists and classi­
fied on the basis of the report of the nomenclature committee (19). 
Patients were classified according to clinical stage and to patho­
logical stage as recommended at the Ann Arbor Conference (7). Pa­
tients' data and weights of the resected spleens are summarized in 
Table 1. 
Table 1. Summary of Patients' Data 
Patient Sex Age Clinical Pathological Histological Splenic 
1. L.v.d.S. 
2. B.H.-.v.U. 
3. H.B. 
4. G.M. 
5. R.d.B. 
6. P.R. 
7. E.R. 
8. M.R.-J. 
9. M.E.-G.E. 
10.R.D. 
ll.A.S. 
12.R.V.B. 
13.P.G.-B. 
14.M.D.-P. 
15.A.V.W. 
F 
F 
M 
M 
F 
M 
F 
F 
F 
M 
F 
F 
F 
F 
M 
34 
28 
47 
30 
27 
56 
33 
24 
39 
18 
17 
18 
40 
48 
34 
staging 
I A 
I В 
I A 
II A 
II В 
II В* 
Il В 
UIA 
UIA 
HIB 
UIA 
HIB 
HIB 
HIB 
IV В 
staging 
I 
I 
I 
II 
II 
II 
II 
II 
II 
II 
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-K-
H-S-N-K-
K-S-WI+M-
H-S-N-y-
H-S-N-M-
H-S-N-M-
H-S-N-I^ 
IIIH-S+N+M-
IHH-S+N-M-
HIH-S-N+M-
nm-s-m+M-
111H-S+N+M-
type *** 
MS 
IP 
MC 
NS 
MC 
MC 
NS 
MC 
NS 
MC 
NS 
MC 
MC 
MC 
MC 
weight 
rather 
290 
115 
365 
180 
470 
245 
160 
120 
420 
185 
460 
480 
185 
543 
* under diaphragm 
** H+ or H- for liver positive or negative ; 
S+ or S- for spleen positive or negative ; 
N+ or N- lymph node positive or negative; 
M+ or M- for marrow positive or negative ; 
*** N.S.: nodular sclerosing 
L.P.: lymphocyte predominance 
M.C.: mixed cellularity 
As controls, healthy volunteers, matched for age and sex, were 
examined for the same parameters of lymphocyte function at the 
same time as the patients before and after splenectomy. 
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Methods 
Blood samples were obtained between the 7th and 1st preoperative 
and the 9th and 11th postoperative day, to start lymphocyte cul­
tures with PHA, a cocktail of antigens and a MLC, and to deter­
mine the relative numbers of Τ and В cells by rosette-forming 
technics. 
Blood samples for lymphocyte counts were obtained on three consec­
utive days before and after the operation. 
Skin testing 
Before laparotomy and about 10 days postoperative, all patients 
received intradermal injections of 0.1 ml Candida albicans extract 
0.5:100 (Bencard, England), Trichophyton allergenic extract 
0.5:100 (Bencard, England), intermediate strength purified protein 
derivative, PPD (10 T.U./ml) (R.I.V., Bilthoven, The Netherlands), 
mumps skintest antigen (Eli Lilly and Co, Indianapolis, USA), and 
streptokinase (SK) - streptodornase (SD), 10 units of SK and 10 
units of SD (Varidase, Lederle Laboratories, Wayne, USA). Skin reac­
tions were evaluated at 24, 48 and 72 hours and induration of 5 
mm or more was considered a positive response. 
Lymphocyte culture 
Lymphocyte cultures were carried out as described by du Bois et al. (9). 
The lymphocytes were separated from defibrinated blood by Ficoll-
Isopaque gradient centrifugation. These cells were washed and re-
suspended in Minimum Essential Medium (MEM-S, Gibco, New York), 
buffered with Tris (0.025 M) pH 7.4. The cells were counted elec­
tronically (model В Coulter Counter). Fresh inactivated human AB 
serum was added up to an endconcentration of 20%. AB serum from 
the same donor was used before and after splenectomy. The medium 
contained penicillin (100 I.U./ml) and streptomycin (100 yg/ml). 
The cell concentration was brought to 0.3 xlO lymphocytes per 
ml. Samples of 1 ml were cultured at 370C in polystyrene vials 
(Nunc 70 χ 11mm Roskilde, Denmark). 
The PHA reactivity was determined by adding 50 yg Phytohämagglu-
tinin (Wellcome MR 10, Beckenham, England). 
A cocktail of antigens was prepared as described by Leguit et al. 
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(18). It contained 5 different antigens (PPD, varidase. Tricho­
phyton antigen, Candida albicans allergenic extract and mumps skin-
test antigen) each in a concentration optimal for lymphocyte trans­
formation. 
Mixed lymphocyte cultures were made by mixing 0.5ml lymphocyte sus­
pension from each Hodgkinfe patient (P) with 0.5ml lymphocyte sus­
pension from an unrelated healthy volunteer (C). Unilateral stimu­
lation was measured by blocking one of the lymphocyte suspensions 
by preincubation during 30 minutes at 370C, with mitomycin-C (A. 
Cristiaans, Brussels, Belgium), final concentration 19.2yg/ml. 
The cultures to which PHA had been added were terminated after 3 
days. The MLC and the cultures to which the antigen cocktail was 
added were harvested on the 6th culture day. 
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To determine DNA synthesis 2- C-thymidine(0.075pCi, specific ac­
tivity 6.25mCi/mmole, Amersham, England) was added 24 hours before 
the cultures were terminated. In harvesting, the cells were col­
lected and eluted on 0.45y g.lass-fibre filters (Millipore Corp. 
Bedford, Mass. U.S.A.) which were then dried. The filters were 
counted for 10 minutes (LKB 81000 Liquid Scintillation Counter) in 
2 ml scintillation fluid (15g PPO and lg POPOP in 2ml toluene). 
All cultures were carried out in triplicate. The normal value with 
s.d. of the PHA response was 7.467 cpm + 2.305 (n=56). 
Ε-binding lymphocytes 
Lymphocytes were isolated from peripheral blood and contaminating 
monocytes were removed according to Zeylemaker (32) by carbonyl-
iron treatment and Ficoll-Isopaque centrifugation. 
Sheep blood was diluted with an equal volume of Alsever's solu­
tion, stored at 40C and used within one week. Before use,erythro­
cytes were washed twice and the concentration adjusted to a 1% 
suspension in Earle's folution. In order to determine the number 
of cells with the ability to form spontaneous rosettes with sheep 
red blood cells(E rosettes), 0.25 ml lymphocyte suspension (about 
10 cells) was mixed with 0.25 ml of red blood cells and incubated 
at 370C for 15 minutes. The mixed cell suspension was spun at 200g 
for 5 minutes, and then incubated in ice overnight. The superna­
tant was then sucked off and the pellet was resuspended by gentle 
shaking. One drop of the cell suspension was mounted on a glass 
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Table 2. Resu l t s of Lymphocyte Count, PHA St imulat ion, Rosette-Forming Capacity, S k i n t e s t -
ing and St imulat ion by a Cockta i l of Antigens in P a t i e n t s with P a t h o l o g i c a l Stages I and II 
before and a f t e r Splenectomy 
l.D.L.-v.d.S. 
2.B.H.-.V.U. 
3.H.B. 
4.G.N. 
S.R.d.B. 
6.P.R. 
7.E.R. 
8.M.R.-J. 
9.M.E.-G.E. 
1UR.D. 
Мэап 
Lynphocyte 
count 
per nm 
before 
1300 
1400 
2200 
1600 
2300 
2700 
1500 
2000 
2000 
2700 
1970 
afl-pr 
1900 
1800 
1800 
1800 
2800 
5900 
2600 
1700 
2100 
2500 
2490 
PHA 
stimulation 
in cpti 
before after 
6397 
5256 
7896 
5375 
7434 
4332 
7143 
9962 
5757 
8915 
6365 
6994 
4607 
5552 
6140 
5241 
5625 
8934 
11952 
8435 
8567 
6807 
E-binding 
lympho­
cytes 
before 
-
-
68 
65 
-
75 
56 
67 
43 
71 
63.6 
in % 
after 
-
-
50.5 
47 
-
61 
50 
72.5 
57 
64 
57.4 
EAC-binding 
lyirpho-
cytes in % 
before after 
-
-
21 
30 
-
21 
21 
19 
38 
22 
24.6 
-
-
30.5 
37 
-
27.5 
33 
25.5 
29.5 
18 
28.7 
Score of 
positive 
skintests 
before after 
4 
2 
4 
3 
3 
2 
1 
3 
2 
2 
2.6 
4 
3 
2 
3 
3 
1 
2 
3 
1 
3 
2.5 
Response to 
cocktail of anti­
gens in cpm 
before after 
-
5011 
4030 
1241 
4035 
-
277 
1374 
734 
4737 
2680 
-
3284 
3822 
2435 
3181 
-
381 
1973 
842 
2901 
2352 
score of the skintest is defined as follows: 5: all skintests are positive, 4: 4 out of S are positive, 
3:3 out of 5 eto. 
slide, covered by a coverslip, and sealed with nail-polish. 200 
lymphocytes in duplicate were examined by two independent techni­
cians. All lymphocytes, binding more than three sheep red blood 
cells, were considered positive (28). The normal value of E-bind-
ing lymphocytes with s.d. was 53% ± 7 (n=18, range 40-65%). 
EAC-binding lymphocytes 
As a test procedure for EAC-rosettes, 5 ml of a 5% suspension of 
washed sheep red blood-cells was incubated for 30 minutes at 37 С 
with 5ml amboceptor (rabbit antiserum against sheep red blood-
cells) diluted 1/2000 in Earle's solution. The cells were washed 
three times and resuspended in 5ml Earle's. Five ml of human com­
plement (fresh serum) diluted 1/20 in Earle's was then added and 
the suspension incubated for 30 minutes at 370C. The cells were 
finally washed three times and adjusted to anl% suspension-0.25ml 
of the prepared suspension of sheep cells (EAC) was mixed 
with an equal volume (10 ) lymphocyte suspension, spun at 200 g 
for 2 minutes and then left at room temperature for 15-30 minutes. 
The supernatant was sucked off and the cells were resuspended by 
vigorous mixing on a whirl-mixer. 400 lymphocytes (200 by each 
technician) were counted under a sealed cover slip (28) . The same 
critetion as for Ε-rosettes was used. The normal value of EAC-bind­
ing lymphocytes with s.d. was 26% + 5 (n=19, range 18-37%). 
Statistical analysis 
Statistical analysis was carried out with the Student's t-test on 
the differences of paired observations. 
RESULTS 
The patients are classified according to pathological stages and 
grouped in two groups. The first group consists of the less ex­
tensive forms, stages I and II, the other group of stage III. 
The first column of Table 2 lists the mean lymphocyte count before 
and after the splenectomy for patients with pathological stages I 
and II, showing a moderate but not significant increase. 
There was no significant difference too, in the PHA test, in E-
binding and in EAC-binding lymphocytes as demonstrated in the 
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next three columns. 
The fifth column of Table 2 shows the results of the skintest-reac-
tivity, indicated by the score of positive tests. There was wide­
spread variation between individual patients, but there were only 
slight differences in the number of positive tests before and 
after operation. 
The last column of Table 2 gives the data of the stimulation of 
the lymphocytes by a cocktail of antigens. Like the skintests 
there was a great difference in reactivity between the various pa­
tients, but there was no significant difference before and after 
splenectomy for the individual patient. 
Table 3 gives the results for the MLC (bilateral, unilateral and 
mitomycin controls) in patients with pathological stages I and II 
before and after the operation. For the whole group no difference 
before and after the surgery was found. However, patient 6 and θ 
showed totally opposite data, since for patient 6 a depression 
of the MLC after the operation was found, whereas patient 8 showed 
an increase in stimulation in the № С . 
Table 4 gives the results of patients with pathological stage III, 
showing no difference in lymphocyte count and a significant in­
crease in PHA stimulation. 
For the whole group there was a slight decrease but no significant 
difference in Ε-binding lymphocytes. 
The score of positive skintests was nearly the same before and af­
ter the operation comparable to the findings in patients with path­
ological stages I and II. 
There were great individual differences between the patients in 
lymphocyte stimulation by an antigen cocktail. All patients showed 
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an increased С-thymidine incorporation after the operation. It 
should be mentioned that patient 14 had septicaemia 7 days be­
fore testing. 
Table 5 gives the data of MLC's for the same patients, showing 
for the group as a whole no clear difference. The stimulation of 
the lymphocytes of patient 12 has diminished after the splenecto­
my. 
The changes in distribution of Ε-binding and EAC-binding lympho­
cytes and PHA stimulation of the lymphocytes in peripheral blood 
before and after the operation for all the patients in correlation 
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Table 4. Results of Lymphocyte Count, PHA-Stimulation and Rosette-Forming Capacity,Skintest-
ing and Stimulation by a Cocktail of Antigens in Patients with Pathological Stage III 
before and after Splenectomy 
1 1 . A . S . 
1 2 . R . V . B . 
1 3 . P . G . - B . 
1 4 . M . D . - P . 
15.A.V.W. 
Mean 
Lymphocyte 
count 
3 
per nm 
PHA Ε-binding EAC-binding Score of 
stimulation lympho- lympho- p o s i t i v e 
in срт cytes in % cytes in % sk intests* 
Response t o 
cocktai l of 
antigens i n cpm 
before after before after before after before after before after before after 
1300 1800 8 7 5 2 7034 35 52 
2700 2700 7863 9322 80 6 0 . 5 
2600 3200 2587 4828 58 3 4 . 5 
2100 2000 2843 6942 51 54 
1100 1000 3613 6777 53 34 
2000 2100 5132 6981**55.4 47 
20 
26 
21 
46 
32 
29 
28 
32 
25 
30 
40 
31 
2 
3 
4 
2 
2 
2 . 6 2 . 4 
1554 2418 
3597 4332 
841 5784 
91 162 
1516 3174 
* score for the skintest is defined as follows: 5: all skintesLs are positive, 4:4 out 
of 5 are positive, 3:3 out of 5 etc. 
**difference significant: p: <0.02. 
Table 3.Results of MLC in Patients with Pathological Stages I and II 
l.D.L.-v.d.S. 
2.B.H.V.U. 
3.H.B. 
4.G.M. 
S-R.d.B. 
6.P.R. 
7.E.R. 
8.M.R.-J. 
9.M.E-G.E. 
XIR.O. 
Mean 
MLC in 
P* + 
cpm 
c** 
before after 
4776 
5944 
4705 
2614 
2212 
4768 
1727 
2567 
-
-
3664 
4983 
4802 
4464 
2890 
2269 
2403 
2194 
4069 
-
-
3509 
MLC in 
Ρ 
before 
3535 
3760 
2355 
727 
738 
2847 
1719 
3275 
-
-
2370 
cpn 
+ Cm*** 
after 
4129 
1456 
2985 
1039 
1551 
1301 
1747 
3898 
-
-
2263 
MLC in 
Pm + 
before 
2168 
3225 
2650 
500 
741 
2405 
865 
1966 
-
-
1815 
cpm 
С 
after 
2635 
1502 
2882 
1091 
1357 
1761 
901 
3437 
-
-
1946 
MLC in 
Pm + 
before 
47 
50 
60 
64 
30 
64 
48 
87 
-
-
56 
cpm 
Cm 
afte: 
50 
37 
72 
77 
38 
88 
64 
82 
-
-
64 
* P=pat-ient 
** C=healthy control 
*** m=mitomyain-treated 
with the splenic weight are summarized in Table 6. There was a sig­
nificant decrease in Ε-binding and a significant increase in EAC-
binding lymphocytes after the operation in patients with splenic 
weights of 240g and more, whereas the PHA stimulation of the lym­
phocytes in these patients increased significantly. There was also 
a significant correlation between the difference in Ε-binding lym­
phocytes before and after operation and the weight of the resected 
spleen. There was no significant correlation between PHA stimulation 
of lymphocytes and splenic weight. No significant difference 
in E- and EAC-binding lymphocytes was found in relation to posi­
tive or negative pathology of the spleen. 
DISCUSSION 
The evaluation of changes in the immunological parameters before 
and after splenectomy was postponed on about the 10 postopera-
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Table 5. Resu l ts of MLC in CPM in P a t i e n t s with P a t h o l o g i c a l Stage I I I 
872 
3868 
2030 
1800 
791 
757 
2479 
2130 
2461 
663 
230 
3040 
1064 
1168 
197 
435 
1381 
1219 
1022 
334 
390 
5423 
923 
994 
123 
89 
2500 
1179 
1987 
341 
56 
51 
43 
29 
34 
64 
46 
39 
72 
34 
MLC MLC MLC MLC 
P * + C** Ρ + On*** Pm + С PM + Cm 
before after before after before after before after 
1 1 . A . S . 
1 2 . R . v . B . 
1 3 . P . G . - B . 
1 4 . M . D . - P . 
1 5 . A.v.W. 
Mean 1872 1698 1140 878 1571 1219 43 51 
* P.- patient 
** C: healthy control 
*** M: mitomycin-treated 
tive date. As stated in our earlier publication (30), this was 
decided to avoid the period of immunosuppressive effect expectw 
ed immediately after the surgical procedure (12,20,21). In addi­
tion the initiation of treatment whether by radiotherapy or chemo­
therapy which would also influence the immune status is not delayed 
beyond the 11 postoperative day (13,26). 
In a previous publication (30) we reported on the effect of splen­
ectomy on the PHA stimulation in Hodgkin's disease. Contrary to 
literature (20,29) we did not find a diminished PHA stimulation 
of peripheral lymphocytes about the 10 t h postoperative day after 
splenectomy in Hodgkin's patients. Park (20) describes, however, 
only 2 patients, with other forms of malignancy and other types 
of operation (bronchogenic carcinoma and pneumonectomy, oesopha­
geal carcinoma and oesophagectomy). Uccellini (29) determined the 
PHA stimulation by morphological interpretation of the blastogen-
esis . As is described by Schellekens (23) it is not possible to 
get reproducible results with this method. 
In the present study a different aspect of the immune response is 
investigated. 
The cellular anamnestic response to antigens studied with skin-
testing and in vitro with a stimulation of lymphocytes by a cock­
tail of antigens was not changed after the operation. 
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Table 6. Changes in Distribution of E-binding, EAC-binding Lymphocytes and PHA Stimulation m 
Peripheral Blood before and after Splenectomy in Correlation with Weight of the Resected Spleen 
Splenic wei 
Patients Splenic 
weight 
(g) 
l.H.B. 115 
2.M.R.-J. 160 
3.M.E.-G.E.120 
4.M.D.-P. 185 
5.A.S. 185 
Mean 
ght less than 
E-binding 
lynfihocytes 
before 
68 
67 
43 
51 
35 
52.8 
200 g 
PHA stimu­
lation 
after before 
50.5 
72.5 
57 
54 
52 
57.2 
5928 
9962 
5757 
2843 
8752 
6648 
EAC-binding 
lynitiiocytes 
after before after 
4206 
11952 
8435 
6942 
7034 
7714 
21 30.5 
19 25.5 
38 29.5 
46 30 
20 28 
28.8 28.7 
Patients 
l.P.R. 
2.E.R. 
3.R.D. 
4.G.N. 
5.R.V.B. 
6.P.G.-B 
7.A.V.W. 
Mean 
Splenic weight rrore 
Splenic 
weight 
(g) 
470 
245 
420 
365 
460 
. 480 
543 
E-binding 
lymphocytes 
than 
PHA-
200 g 
stimu-
lation 
EAC-binding 
lymphocytes 
before after before after before after 
75 
56 
71 
65 
80 
58 
53 
65.4 
61 
50 
64 
47 
60.5 
34.5 
34 
50.1* 
3282 
7143 
8915 
5375 
7863 
2587 
3613 
5540 
4264 
8934 
8567 
6140 
9322 
4828 
6777 
21 27.5 
21 33 
22 18 
30 37 
26 32 
21 25 
32 40 
6976** 24.7 30.4** 
Differenae sigmfzcant : 
* ρ : 0 . 0 01 
* * ρ : 0. 01S 
*** ρ:0.023 
Correlatbon aoeffiaient between splenic weight and difference in number of Τ lymphocytes be­
fore and after splenectomy : 0.712; p: 0.009. 
The response to a cocktail of antigens seems to have improved after 
splenectomy in patients with pathological stage III. Patient 14 
(M.D.-P.) with the highest increase of the stimulation by an 
antigen cocktail had septicaemia 7 days before the examination. 
Whether this had any influence is not clear. 
A remarkable finding is that the number of Ε-binding lymphocytes 
(T-lymphocytes) in the peripheral blood in all cases studied de­
creased when the spleen weight increased (more than 240 g). 
Belpomme (3) reported that the mean percentage of T-lymphocytes 
in spleens with histological evidence of Hodgkin's disease was 
significantly higher than that in the non-malignant spleens. Al­
though he made no correlation between the increase of T-lymphocytes 
with splenic weights, it is noted in his published table that 
such a correlation exists. As an explanation one can speculate 
that the removal of many Τ cells, contained in the enlarged spleen, 
could result in a decrease of Ε-binding lymphocytes in the periph­
eral blood. 
An interesting point is that in patients with a resected spleen 
of 240 grams and more the PHA stimulation of the lymphocytes in­
creased significantly, whereas the relative proportion of E-bind-
ing lymphocytes decreased significantly. Although the numbers 
of cases studied is rather small, it seems justified to conclude 
that the PHA test does not run always parallel with the relative 
proportion of Ε-binding lymphocytes. Therefore, one has to be 
careful in making conclusions about the percentage of T-cells de­
termined only with PHA stimulation. 
Results of lymphocyte stimulation by allogeneic cells (MLC) showed 
no clear differences before and after splenectomy. Mixed lym­
phocyte culture depends upon immunogenetic differences at, or 
related to the HLA locus. MLC-reactivity may be considered to 
be antigen specific (2,24). PHA stimulation gives an aspecific 
reaction of lymphocytes. Quantitatively, chronologically and bio­
chemically PHA stimulation differs from specific antigen stimu -
lation, although it is morphologically similar. This is the reason 
why MLC seems more relevant. Therefore, it has to be concluded, 
that there is no improvement of the immunological competence, as 
suggested by the PHA test for the more extensive forms of Hodgkin's 
disease after the splenectomy, but that the immunological status 
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does not change before and after the splenectomy. 
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ABSTRACT 
Humoral immunological competence was evaluated by the measurement 
of immunoglobulin levels and various antibody titres in 30 un­
treated Hodgkin's patients before and about 10 days after splenec­
tomy. These data were compared with those obtained in a control 
group of patients,who underwent laparotomy for other reasons. 
After splenectomy a highly significant (p=0.001) drop in IgG level 
was found in Hodgkin's patients stage I and II, whereas IgG levels 
in patients with stage III and IV and the control surgery group 
remained at the same level. 
The IgM content diminished slightly in Hodgkin's patients stage I 
and II, and significantly (p=0.04) in stage III and IV. In the 
control group however, a significant (p=0.00 8) increase in Igit 
level was found. 
The IgA level increased significantly (p=0.03) in patients with 
Hodgkin's disease stage I and II and in the controls (p=0.01). 
The E.coli antibody titre increased after the operation in both 
groups of patients although the rise in the control surgery 
group was significantly higher (p=0.003). 
Antistreptolysin titre did not change in Hodgkin's and control 
patients. 
The titres of blood group antibody anti-Α and anti-B before and 
after operation showed great individual variation, but no differ­
ence between Hodgkin's and control group patients was found. 
The whole complement level increased significantly after opera­
tion in Hodgkin's (p=0.0002),as well as in surgery patients 
(p=0.00004) . 
The data are discussed in the light of the possible increased in­
fection rate after splenectomy in general, and in Hodgkin's dis­
ease in particular. 
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INTRODUCTION 
In an earlier study about the influence of splenectomy on immuno­
logical parameters in Hodgkin's disease it was concluded that no 
demonstrable untoward effect was found on cellular immunological 
potency (24,25). Two striking findings in that study were the 
significant increase in PHA stimulation of peripheral lymphocytes 
in stages III and IV and a significant decrease in Ε-binding lym­
phocytes in patients with splenic weight of 240 g and more. 
In this paper the effect of splenectomy on humoral immunity in 
patients with Hodgkin's disease is reported. The humoral immune 
profile investigated is the antibody forming capacity as measured 
by immunoglobulin levels, isohemagglutinin titres, antistrepto­
lysin titres, E.coli antibody titres and complement levels. 
PATIENTS AND METHODS 
Patients 
30 newly admitted untreated Hodgkin's patients were examined. The 
histological classification used was that of the Rye Conference 
(12). Patients were classified in 4 stages according to the Ann 
Arbor Conference (1). Patients' data and weights of the resected 
spleens are summarized in Table 1. Patients who underwent laparot­
omy for other reasons (cholecystectomy: 9 cases, partial gastrec­
tomy: 3 cases, choledochotomy: 1 case, selective vagotomy: 1 case) 
were used as controls. 
Methods 
Blood samples were collected between the 7th and 1st preoperative 
and the 9th and 11th postoperative day. After 30 minutes the clott­
ed blood was centrifuged. The serum was decanted and stored at 
-70oC. 
Immunoglobulins 
Quantitative estimations of IgG, IgM and IgA in serum ware per­
formed with an automated turbidimetric immunoprecipitation method 
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Table 1. Summary of Patients' Data 
Patient 
1. D.L.-v.d.S. 
2. G.L.-H. 
3. A.H. 
4. H.B. 
5. B.H.-v.U. 
6. E.M. 
7. M.L.-H. 
8. J.V.O. 
9. M.J.-V. 
10.J.V. 
H.MvdE-GvdE. 
12.G.B.-M. 
13.M.R.-J. 
14.W.P. 
15.E.R. 
16.R.d.B. 
17.W.T.-S. 
18.N.S. 
19.R.D. 
20.E.L. 
21.M.U. 
22.A.K.-T. 
23.A.V.d.K. 
24.A.S. 
25.P.G.-d.B. 
26.R.V.d.B. 
27.M.v.D.-d.P. 
28.A.V.W. 
29.J.B. 
30.G.H. 
Sex 
F 
F 
M 
M 
F 
M 
F 
M 
F 
F 
F 
F 
F 
M 
F 
F 
F 
F 
M 
M 
M 
F 
M 
F. 
F 
F 
F 
M 
M 
M 
Age 
34 
26 
26 
47 
28 
37 
21 
43 
44 
20 
39 
26 
24 
22 
33 
27 
47 
31 
18 
60 
49 
35 
30 
17 
40 
18 
48 
34 
26 
28 
Clinical 
staging 
I A 
I A 
I A 
I A 
I В 
I В 
II А 
II А 
II А 
ІІІА 
ІІІА 
UIA 
UIA 
II В 
II В 
II В 
II В 
II в 
HIB 
ІІІА 
UIA 
II А 
UIA 
UIA 
HIB 
HIB 
HIB 
IV в 
IV в 
IV в 
Pathological 
staging 
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-M-
H-S-N-l^ 
H-S-N-M-
HIH-S-N-tM-
IIIH-S-W-M-
IIIH-S+N-M-
IIIH-S+N+M-
IIIH-S+N+M-
IIIH-S-N4M-
IHH-S+N-M-
IIIH-S-HSI-НУ!-
IIIH-S+N+M-
IV H+S+N+M-
Г H+S+N-tM-
Histologi-
cal type 
N.S. 
M.C. 
M.C. 
M.C. 
L.P. 
L.D. 
N.S. 
L.P. 
M.C. 
L.P. 
N.S. 
N.S. 
M.C. 
N.S. 
N.S. 
M.C. 
M.C. 
L.D. 
M.C. 
L.D. 
L.P. 
N.S. 
M.C. 
N.S. 
M.C. 
M.C. 
M.C. 
M.C. 
N.S./M.C. 
M.C. 
Splenic 
weight (g) 
rather small 
150 
230 
115 
290 
153 
330 
80 
275 
140 
120 
360 
160 
390 
245 
180 
370 
300 
420 
140 
153 
120 
230 
185 
480 
460 
185 
543 
283 
270 
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Table 2. Immunoglobulin Levels before and after Splenectomy in 
Hodgkin's Patients with Pathological Stages I and II 
Patient 
D.L.-v.d. 
G.L.-H. 
H.B. 
B.H.-v.U. 
E.M. 
M.L.-H. 
J.V.O. 
M.vdE.-G. 
G.B.-M. 
M.R.—J· 
W.P. 
E.R. 
J.d.B. 
W.T.-S. 
N.S. 
R.D. 
Mean + s. 
,S. 
• vdE 
.d. 
IgG 
mg/ml 
before 
11.0 
12.4 
10.4 
14.7 
16.4 
15.7 
8.4 
. 14.4 
16.7 
15.7 
8.7 
16.9 
17.7 
18.1 
14.1 
12.7 
1.40+3.1 
after* 
11.0 
11.7 
9.0 
13.7 
13.7 
11.7 
6.7 
13.2 
13.4 
13.7 
8.7 
13.3 
15.7 
17.1 
11.7 
15.1 
12.5+2.7 
IgM 
mg/ml 
before 
3.75 
2.03 
1.41 
2.07 
1.97 
2.23 
5.43 
0.80 
1.70 
2.71 
0.72 
1.09 
3.03 
4.15 
0.67 
1.14 
2.18+1.35 
after** 
3.75 
1.66 
1.17 
1.97 
1.62 
2.87 
4.15 
0.96 
1.70 
2.79 
0.85 
0.73 
2.39 
3.24 
0.74 
1.10 
1.98+1.11 
IgA 
mg/m 
before 
2.22 
2.18 
2.68 
2.37 
4.59 
1.84 
4.67 
3.10 
3.52 
2.68 
2.68 
3.86 
4.13 
1.91 
2.68 
3.44 
3.03+0.91 
1 
after*** 
2.68 
2.29 
3.06 
2.83 
4.51 
2.60 
4.90 
3.30 
3.67 
3.21 
2.91 
4.98 
3.90 
1.91 
2.22 
3.21 
3.26+0.92 
Signifiaance of differenoe before-after : 
* p=0.001 
** p=0.091 
*** p-O.0Z7 
(14) and expressed in mg/ml. Pairs of pre- and postoperative sam­
ples were analysed simultaneously. Normal adult laboratory values 
(mean + s.d.) with this method are: 
IgG: 11.0+ 2.5 mg/ml (n=102); IgM male 1.24 + 0.44 mg/ml (n=40); 
IgM female: 1.47 + 0.36 mg/ml (n=55) ; IgA: 2.00 + 0.70 mg/ml 
(n=98). 
Antibodies 
Bloodgroup antibodies anti-Α and anti-B 
Titres of blood group antibodies anti-Α and anti-B were determined 
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with A. and В erythrocytes as follows: 
a.complete antibodies (predominantly IgM) were titrated in saline 
at room temperature ; 
b.incomplete antibodies (mainly IgG) were titrated in indirect 
antiglobulin test after neutralization of complete antibodies 
with porcine and equine AB substance (Metrix, Armour Pharma­
ceutical Company, Chicago, Illinois, U.S.A.) for one hour at 
room temperature. 
The titres were measured in duplicate and expressed as the highest 
titre. The difference between the two determinations never ex­
ceeded 1, on a logarithmic scale with a base of 2. 
E.aoli antibodies 
The titres of E.coli agglutinins were determined by the method of 
Webster et al. (26). The polyvalent antigen consisted of six 0 
types of E.coli which are commonly found in the Netherlands. The 
strains were supplied by Dr.P.Guinee, R.I.V. Bilthoven, The Nether­
lands, and were of the following 0-types:0 , 0 , 0
Я
, 0.,., 0__and 0-
The titres were measured in duplicate and expressed as the highest 
titre. 
Antistreptolysin titres 
Antistreptolysin titres were tested in duplicate by the method of 
van der Veen (23) adapted for microtitre-equipment. 
Complement 
Whole complement assays were performed according to Kabat and 
Mayer (9) . 
Statistical analysis 
Statistical analysis was carried out with the Student's t-test on 
the differences of paired observations for comparing pre- and post­
operative values for immunoglobulin- and complement levels. 
The Student's t-test for two samples was used to compare the dif­
ference in pre- and postoperative value for the immunoglobulin-
and complement level in the Hodgkin's and control surgery group. 
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For comparing pre- and postoperative E.coli agglutinin titres the 
Wilcoxon's test for symmetry was used. 
To test the difference in rise in E.coli antibody titre between 
Hodgkin's and control patients the Wilcoxon's two samples test was 
done. 
RESULTS 
The patients are classified according to pathological stages and 
grouped in two groups. The first group consists of the less ex-
tensive forms, stages I and II, the other group of stages III and 
IV. 
As shown in Table 2,3,4 and 5 the IgG level decreased significant-
Table 3. Immunoglobulin Levels before and after Splenectomy in 
Hodgkin's Patients with Pathological Stages III and IV 
Patient IgG IgM IgA 
mg/ml mg/ml mg/ml 
before after* before after** before after*** 
M.U. 
A . K . - T . 
A . V . d . K 
A . S . 
P . G . - d . B , 
R . v . d . B . 
M . v . D . - d . 
A . v . W . 
J . B . 
G.H. 
Mean + s. 
. P . 
. d . 
1 1 . 4 
1 4 . 4 
1 5 . 7 
1 3 . 9 
1 6 . 7 
1 3 . 7 
1 1 . 0 
1 5 . 7 
9 . 4 
1 3 . 5 
13.5+2.3 
1 4 . 7 
1 9 . 6 
1 7 . 4 
1 5 . 3 
1 5 . 7 
1 5 . 4 
9 . 4 
1 5 . 7 
8 . 4 
1 2 . 6 
14.4+3.4 
1 .14 
2 . 1 1 
2 . 1 8 
2 . 8 1 
1.52 
2 . 7 1 
1.09 
0 . 9 8 
0 . 8 0 
1.40 
1.67+0.73 
1 .28 
1.56 
2 . 0 7 
2 . 7 0 
1.44 
2 . 0 7 
0 . 7 3 
0 . 9 6 
0 . 8 0 
1 .25 
1.49+0.63 
2 . 9 1 
3 . 0 5 
4 . 6 7 
2 . 2 9 
5 . 8 9 
3 . 4 4 
4 . 9 8 
3 . 9 8 
0 . 9 2 
2 . 8 4 
3.50+1.44 
3 . 8 2 
3 .20 
5 . 5 8 
2 . 9 5 
4 . 3 6 
4 . 3 6 
3 .66 
4 . 3 6 
0 . 9 2 
2 . 9 0 
3.61+ 
Signifioanae of difference before-after: 
* p=0.P,S9 
** p-0.041 
*** p=0.163 
ly postoperatively in patients with Hodgkin's disease stages I and 
II (p=0.001) and remained at the same level in patients with stages 
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Table 4. Immunoglobulin Levels before and after the Operation in the Control Surgery Group 
Patient 
A.v.B.-G. 
E.N.-L. 
H.L.-G. 
H.L. 
P.H. 
F.K. 
H.K. 
Ε.ν.Η.-О. 
Κ. Β.-Η. 
C.v.W. 
H.N. 
Mean + s. 
Operation 
cholecystectomy 
cholecystectomy 
cholecystectomy 
cholecystectomy 
cholecystectomy 
cholecystectomy 
cholecystectomy 
cholecystectomy 
selective vagotomy 
partial gastrectomy 
Billroth II 
partial gastrectomy 
Billroth II 
.d. 
IgG mg/1 
before 
9.7 
15.3 
16.7 
11.0 
14.4 
13.5 
13.4 
12.4 
14.0 
8.5 
10.2 
12.7+2.5 
after* 
9.5 
13.5 
13.0 
12.4 
12.8 
12.6 
15.7 
13.4 
15.3 
9.2 
10.8 
12.6+2.08 
IgM mg/1 
before 
1.87 
1.72 
2.39 
2.05 
1.92 
2.26 
1.52 
1.28 
1.48 
1.04 
0.88 
1.67+0.48 
after** 
4.27 
3.28 
2.71 
5.43 
1.77 
2.03 
2.55 
1.49 
6.14 
2.44 
3.33 
3.22+1.50 
IgA 
before 
0.71 
3.10 
4.36 
4.13 
1.52 
3.50 
2.30 
2.30 
2.84 
2.13 
3.23 
2.74+1.09 
mg/1 
after*** 
1.27 
3.20 
4.74 
4.21 
1.32 
3.20 
2.98 
2.68 
3.76 
2.95 
4.57 
3.17+1.15 
Significance of difference before-after: * p-0.852 
** p=0.008 
***p=0.016 
Table 5 . Immunoglobulin Leve ls before and after Splenectomy i n Hodgkin's P a t i e n t s and i n the 
Control Surgery Group 
Group Number of 
patients 
IgG 
mean + s.d. 
mg/ml 
before after 
IgM 
mean + s.d. 
mg/ml 
before after 
IgA 
mean + s.d. 
mg/ml 
before after 
Hdg.St.I+II 16 
Hdg.St.III+IV 10 
controls 11 
14.0+3.1 12.5+2.7* 2.18+1.35 1.98+1.11** 3.03+0.91 3.26+0.92 
13.5+2.3 14.4+3.4 1.67+0.73 1.49+0.63***3.50+1.44 3.61+1.25 
12.7+2.5 12.6+2.1 1.67+0.48 3.22+1.50 2.74+1.09 3.17+1.15 
Significance of difference in •patients with Hodgkin's disease stages I and II in comparison 
with the difference in the controls : 
*p = 0.02 
**p = 0.00024 
Significance of difference in patients with Hodgkin's disease stages III and IV in comparison 
with the difference in the controls: 
***p - 0.0025 
Ill and IV. In comparing the IgG levels in patients with Hodgkin's 
disease stagesl and II, the difference in the level between the two 
stages was significantly (p=0.02) noticable than the difference 
in the IgG level before and after surgery in the control group. 
The IgG level in the control surgery group of patients did not 
change. 
The IgM content diminished slightly in Hodgkin's patients in group 
1 (stagesl and II) and significantly (p=0.04) in group 2 (staggili 
and IV). In the control group however, a significant increase in 
IgM level was found (p=0.008). The difference found in IgM level 
before and after the splenectomy in both groups of Hodgkin's dis-
ease (stagesI/II and stagesIII/IV) differed significantly from 
the difference in the control surgery group (respectively p=0.00024 
and p=0.0025). 
The IgA level increased significantly (p=0.037) in patients with 
Hodgkin's disease (stagesl and II), and in the controls (p=0.01), 
after the operation. The IgA level did not change significantly 
after the splenectomy in Hodgkin's patients stages III and IV. 
In Table 6 the effect of splenectomy on antibody level anti-A 
and anti-B is shown. There were great individual differences. 
Patient G.L.-H. showed a remarkable rise in titre. One day after 
the operation she got two bottles of O-Rh negative blood. The 
logarithmic rise of complete antibodies was 11 times and of incom-
plete antibodies 5 times. There was no difference in increase 
between Hodgkin's and control group patients. The increase of an-
tibody titre is not reflected in the immunoglobulin levels. 
Table 7 and figure 1 give the data of E.coli agglutinins before 
and after the laparotomy. The rise in titre has been recorded on 
a logarithmic scale with a base of 2 (i.e. a rise from 2 to 8 = 2 
etc.). There is a significant increase in E.coli agglutinin titre 
in the non-mercaptoethanol treated as well as in the mercaptoetha-
nol treated sera in Hodgkin's patients after splenectomy (resp. 
p=0.021, p=0.012) and in the control surgery group ( p= 0.016 for 
both ). The rise in titre found in the control surgery group, 
however, is significantly higher than in Hodgkin's patients (p= 
0.003). The titres from the mercaptoethanol treated sera indicate 
that the main antibody type is of the IgM type. 
There is no difference in antistreptolysin titre before and after 
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Table 6. Titre of Antibodies anti-A and anti-B in Comparison with 
and Control Surgery Patients in 
Hodgkin's 
patients 
G.L.-H. 
H.B. 
M.vdE-GvdE. 
R.D. 
W.P. 
D.L.v.d.S. 
B.H.-v.U. 
M.R.-J. 
J.d.B. 
P.G.-d.B. 
R.v.d.B. 
M.v.D.-d.P. 
A.v.W. 
Control 
surgery 
patients 
C.W. 
K.B.H. 
H.N. 
H.L. 
P.L.-G. 
Bloodgroup 
А Ю 
Rhesus (D) 
0-
C4-
Of 
Of 
B+ 
A+ 
A+ 
A+ 
A+ 
A+ 
A+ 
A+ 
A+ 
Of 
0-
O 
O-
0+ 
Titre 
anti 
before 
256 ! 
256 
1024 
64 
64 
64 
128 
32 
32 
1024 
: complete antibodies 
A 
aftpr 
512000 
1024 
512 
512 
256 
1024 
512 
1024 
512 
512 
anti 
before 
128 
64 
64 
64 
64 
64 
512 
256 
128 
64 
16 
128 
16 
32 
64 
16 
1024 
В 
after 
256000 
2048 
256 
512 
128 
64 
1024 
256 
256 
64 
32 
128 
256 
256 
512 
512 
512 
IgM 
mg/ml 
before 
2.03 
1.41 
0.80 
1.14 
0.72 
3.75 
2.07 
2.71 
3.03 
1.52 
2.71 
1.09 
0.98 
1.04 
1.48 
0.88 
2.05 
2.39 
after 
1.66 
1.17 
0.96 
1.01 
0.85 
3.75 
1.97 
2.79 
2.39 
1.44 
2.07 
0.73 
0.96 
2.44 
6.14 
3.33 
5.43 
2.71 
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Immunoglobulin Levels before and after Splenectomy in Hodgkin's 
Relation with Bloodtransfusion 
Titre incomplete 
anti A 
before 
256 
32 
512 
0 
8 
after 
4000 
256 
512 
64 
8 
antibodies 
antd 
before 
128 
16 
512 
1 
0 
1 
2 
8 
8 
2 
0 
128 
. В 
after 
4000 
64 
256 
16 
0 
2 
2 
8 
8 
8 
0 
128 
IgG 
mg/ml 
before 
12.4 
10.4 
14.4 
12.7 
8.7 
11.0 
14.7 
15.7 
17.7 
16.7 
13.7 
11.0 
13.9 
after 
11.7 
9.0 
13.1 
15.1 
8.7 
11.0 
13.7 
13.7 
15.7 
15.7 
15.4 
9.4 
15.3 
Blood-
trans­
fusion 
+ 
-
+ 
+ 
-
-
-
+ 
-
+ 
+ 
-
-
16 
64 
8 
0 
16 
256 
512 
8 
128 
16 
0 
64 
8 
0 
128 
16 
256 
64 
1024 
64 
8.5 
14.2 
10.2 
11.0 
16.7 
9.2 
15.3 
10.8 
12.4 
13.0 
-
-
-
+ 
+ 
Operation in Hodgkin's and surgery patients (Table 8). 
The whole complement level increased significantly after operation 
in Hodgkin's (p= 0.0002) as well as in surgery patients (p=0.00004) 
(see Table 9). The increase in complement level in Hodgkin's pa-
tients after surgery, was significantly (p=0.01) lower than in 
the control group. 
Table 7. Logarithmic Increase in E.coli Agglutinin Titre in Hodg-
kin's and Control Surgery Patients before and after Operation 
Group No of patients Mean logarithmic rise in 
agglutinin titre 
without MEt after ME 
treatment treatment 
Hodgkin's 14 1.3* 1.0** 
patients 
Surgery 7 4.7 2.9 
patients 
Significance of difference in Hodgkin's patients compared to sur-
gery patients:* p=0.003 **p=0.003 
tME- mercaptoethanol 
DISCUSSION 
Splenectomized individuals, especially infants and children, may 
exhibit undue susceptibility to severe and fulminating bacterial 
sepsis (4,5,6,8,10,15,21). Desser and Ultmann(3) discussed pos-
sible increased risks of severe infections after splenectomy for 
Hodgkin's disease or lymphoma. They summarized the data from 12 
institutions in which a total of 1170 splenectomies were performed, 
9 34 in patients with Hodgkin's disease and 236 in patients 
with lymphoma. There were 16 episodes of bacteremia that did 
not seem to be immediate postoperative complications or to occur 
during periods of toxicity associated with therapy. The overall 
figures indicate a morbidity of 1.4% and a mortality of 0.5%. 
This is substantially less than that reported for infections 
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after splenectomy for other reasons. Unfortunately not 
all details from the studied group were available. A rational 
assessment of the risks of splenectomy therefore, was not oossi-
ble at that time. Since the spleen contains considerable amounts 
of immunological active lymphoid cells, it is conceivable, that 
removal of the spleen could cause an impaired humoral immunolog-
ical response against bacterial infections. 
Figure 1. Results of E.coli Agglutinin Titre before and after 
Splenectomy in Patients with Hodgkin's Disease and Control Sur-
gery Patients 
16000
 n 
¿000-
1000 
Hodgkin's 
patients controls 
с 
'с 
en 
σι 
о 
о 
о 
ω 
256 
64-
16-
U-
before ι after before • after 
From animal experimental studies it is known, that the spleen is 
an important site of antibody production (16,17,19,22). 
In human the reported findings about immunoglobulin levels after 
splenectomy vary considerably. Mondorf et al. (13) and Zierott (27) 
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Table 8. Antistreptolysin Titre in Hodgkin's and Control Surgery 
Patients before and after Operation 
Antistreptolysin titre (U/ml) 
before after 
Hodgkin's G.L.-H. 
Patients H.B. 
B.H.-v.U. 
M.vdE.-GvdE. 
E.R. 
W.P. 
A.v.W. 
M.v.D.-d.P. 
400 
200 
800 
300 
50 
75 
300 
200 
300 
150 
1200 
300 
50 
75 
300 
200 
Surgery 
Patients 
C.W. 
K.B.H. 
H.N. 
H.L. 
P.L.-G. 
E.v.H.-O. 
A.v.B.-G. 
50 
<50 
100 
100 
150 
<50 
75 
50 
<50 
100 
50 
150 
<50 
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studied 1-10 years after operation immunoglobulin levels in 31 
persons, who underwent splenectomy because of traumatic splenic 
rupture and in 12 persons for other reasons. They found a signi-
ficant decrease of IgM level, with a normal IgG and IgA content. 
Constantoulakis (2) however, found in 19 patients with ß-thalas-
semia after splenectomy a drop of IgM with the lowest levels 
after 6 months, which gradually increased to reach presplenectomy 
values 2 to 4 years later. IgG and IgA, on the contrary, showed 
a continuous and gradual augmentation after the operation. Sei-
tanidis (20) studied 22 splenectomized patients with ß-thalasse-
mia 1-8 years after operation and found higher levels of IgG and 
IgA, while IgM levels were almost the same as in the control group. 
We found in the present study, that after splenectomy in Hodgkin's 
patients stage I and II, there is a drop in IgG and IgM levels and 
in patients with stage III and IV a drop of IgM level, whereas 
the IgM level in control surgery patients increased significant-
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Table 9. Whole Complement Levels before and after Operation in 
Hodgkin's and Control Surgery Patients 
Hodgkin's Complement Control Complement 
patients U/nl patients U/ml 
before after* before after** 
A . H . 
M . L . - H . 
J . V . O . 
M . J . - V . 
J . V . 
M . R . - J . 
G . B . - M . 
E . L . 
E . M . 
B . H . - v . U . 
C . T . - S . 
J . d . B . 
W . P . 
R . v . d . B . 
A . v . W . 
P . G . d . B . 
5 1 . 5 
4 0 . 8 
5 4 . 0 
6 0 . 4 
4 7 . 0 
5 8 . 1 
7 0 . 0 
6 7 . 0 
6 7 . 8 
G 1 . 3 
6 2 . 6 
1 0 2 . 7 
9 2 . 2 
7 6 . 2 
7 0 . 0 
8 9 . 6 
6 9 . 3 
6 6 . 6 
6 3 . 2 
7 7 . 0 
6 9 . 8 
7 4 . 9 
7 3 . 5 
7 3 . 7 
7 3 . 5 
5 2 . 6 
8 7 . 3 
1 2 2 . 9 
9 0 . 1 
9 3 . 0 
8 5 . 3 
1 0 2 . 8 
D . d . B . 
H . L . - G . 
A . v . B . - G . 
F . K . 
E . N . - L . 
E . v . H . - O . 
C . v . W . 
H . N . 
K . B . H . 
H . ν . К . - W . 
G . L . 
4 8 . 0 
6 1 . 3 
6 8 . 8 
6 0 . 2 
4 9 . 6 
6 1 . 3 
4 5 . 3 
5 4 . 0 
5 4 . 6 
4 9 . 1 
6 1 . 7 
6 5 . 7 
9 3 . 0 
7 7 . 2 
7 0 . 5 
6 2 . 9 
1 0 4 . 0 
7 3 . 7 
7 8 . 9 
8 2 . 7 
8 0 . 1 
7 4 . 7 
Mean + s . d . 6 7 . 0 + 1 6 . 7 7 9 . 7 + 1 7 . 0 5 5 . 8 + 7 . 4 7 8 . 5 + 1 1 . 8 t 
Significance of difference before-after: * p= 2.10 
** ρ- 4.10~5 
Significance of difference in rise between Hodgkin's and control 
group patients: t p- 0.01 
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ly. 
As pointed out by Webster (26) the measurement of antibody to 
pooled E.coli antigen is a useful screening test for impaired an­
tibody production. In the present study E.coli antibodies (main­
ly of the IgM type) were found to be increased after splenectomy 
in Hodgkin's and control surgery patients, but the rise in the 
surgery group was significantly higher than in the Hodgkin's 
group. The high increase in E.coli agglutinins is possibly caused 
by handling the bowel during laparotomy. The patient who underwent 
choledochotomy, a less complicating operation, showed the slightest 
rise. Whether manipulation in the control surgery group is higher 
than in the explorative laparotomy group is difficult to access. 
A higher rate of postoperative infections in splenectomized pa­
tients is possibly related to the observed drop in IgG level and 
the absence of a rise in IgM level. The less intensive rise in 
titre of E.coli antibodies in Hodgkin's patients is an.argument 
in favour of this assumption. 
Antistreptolysin titre did not change in Hodgkin's and control pa­
tients . 
Anti-Α and anti-B isoagglutinin titres in Hodgkin's disease patients 
are normal (7). Antibodies anti-Α and anti-B in patients with blood-
group 0 increased after surgery in Hodgkin's patients as well as 
in control patients. Unfortunately all control patients were of 
bloodgroup 0. An interesting finding is, that the antibodies anti-
A and anti-B were the only antibodies, which showed no difference 
in the postoperative rise in Hodgkin's and control patients. It 
possibly suggests, that the spleen is not important in the produc­
tion of these antibodies, and that the operation per se has a stim­
ulating influence. 
A significant rise in whole complement level was observed in Hodg­
kin' s and control group patients. To our knowledge there is no 
study about the effect of surgery on complement levels. The in­
crease is possibly due to the fact that every injury causes an in­
flammatory reaction (11) and it is known that the complement sys­
tem plays an important role in such a reaction. The reason why the 
increase in complement in control surgery patients is more pro­
nounced than in Hodgkin's patients is not clear. One could specu­
late that this is caused by removal of the spleen, which possesses 
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much macrophages/ the cellular source of most complement proteins 
(18) . 
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ABSTRACT 
The whole complement level was studied and correlated with stag-
ing in 4 3 Hodgkin's patients. In addition a comparison was made 
with other biological signs. 
Highly significant increase (p=10 ) of the mean whole complement 
level was found in stages IIIA and IVA and in all stages with 
systemic symptoms. The complement level in patients with less ex-
tensive forms without systemic symptoms (stagesIA and IIA) did 
not show a significant increase over the controls. 
The best initial parameters which correlated well with disease ac-
tivity were whole complement level, ESR and fibrinogen level. 
It is concluded that whole complement level can give additional 
information and could be of help in differentiating between favour-
able and unfavourable forms of Hodgkin's disease. 
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INTRODUCTION 
It is generally accepted that an immunological defence mechanism 
against tumors exists. The study of the complement system, one of 
the important effector systems of the immunological reaction in 
general, seems therefore meaningful. Southam and Goldsmith (1) did 
not find clear difference in whole complement levels in Hodgkin's 
patients and control persons. Schier and associates (2) and Rottino 
(3), however, using a different technic of complement assay, re­
ported elevated complement levels in Hodgkin's patients compared 
to normal persons. In patients with Hodgkin's disease Southam and 
Siegel (4) found increased levels of the second component (C-) of 
complement whereas Balzola (5) reported increase of С', and C'. 
levels. Irunberry and Colonna (6) found increased C', levels in 
the majority of patients with active disease. 
In the previously mentioned publications, treated as well as un­
treated Hodgkin's patients were studied. No correlation was made 
with the clinical and pathological staging. 
To achieve a better understanding of'the importance of the com­
plement system in Hodgkin's disease, we studied the correlation 
between whole complement levels and staging in untreated patients. 
In addition, the complement levels were correlated to other biolog­
ical signs such as: erythrocyte sedimentation rate (ESR), fibrin­
ogen - and a^-globulin levels and leukocyte- and lymphocyte counts. 
MATERIAL AND METHODS 
Patients 
Forty-three consecutively admitted,untreated Hodgkin's patients 
were examined. The histological classification used was that of 
the Rye Conference modification of Lukes Butler classification (7). 
Patients were classified according to clinical stage and according 
to pathological stage as determined at the Ann Arbor Conference 
(8). Patients' data are summarized in columns 1-6 of table 1,2,3 
and 4. Five patients with stage IV disease and one patient with 
stage HIB were only classified on clinical grounds, because of 
the severity of their illness. Four patients were not submitted 
to explorative laparotomy, because of commitment to the E.0.R.T.C.-
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trial which requires a randomization between laparotomy and no 
laparotomy in clinical stages I and II. 
When laparotomy was performed, patients were classified according 
to pathological stage otherwise on clinical criteria. Patients 
were grouped in 4 groups as follows: A: without general symptoms: 
Group 1: stages IA and IIA, Group 2: stagesIIIA and IVA; В: with 
general symptoms: Group 3: stages IB and IIB »Group 4: stagesIIIB 
and IVB (Table 1,2,3,4 and Fig. 1). 
Fig.l. Results of Whole Complement Level Assay, E.S.R., Fibrinogen 
Amount, a^-Globulin Concentration, Leukocyte and Lymphocyte Count 
in Hodgkin's Patients in Relation with Staging 
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complement ESR fibrinogen аг- globulin leukocytes lymphocytes 
None of t h e p a t i e n t s had c o n c o m i t a n t o v e r t i n f e c t i o u s d i s e a s e . 
H e a l t h y donors from t h e Blood T r a n s f u s i o n S e r v i c e s e r v e d as normal 
c o n t r o l s . 
Methods 
Venous blood was collected in a conventional manner. After 30 mi­
nutes the clotted blood was centrifuged. The serum was then decan­
ted and stored at -70oC. 
Whole complement assays were performed according to the method of 
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Table 1. Surmary of Patients' Data and Results of Vahóle Complement level Assay, E.S.R., Fibrinogen imount, ctj-
00 
о Globulin Concentration, Leukocyte and Lyirphocyte Count in Patients vdth Stages IA and IIA (group 1) 
Patients Age Sex Histo- Staging** Ccmplement E.S.R. Fibrinogen ou-Glòbulin Leukocytes Lymphocytes 
logy* CSt PSft u/ml mm mg/l g/1 χ 109/1 χ 109/1 
1 hr 
1. D.L.-S. 
2. A.H. 
3. H.B. 
4. J.D. 
5. J.O. 
6. J.V. 
7. M.L.-H. 
8. M.E.-G.E 
9. M.J.-V. 
10.M.R.-J. 
11.A.H.-H. 
35 
26 
47 
19 
43 
20 
21 
.39 
44 
24 
43 
Patients mean + 
F 
M 
M 
M 
M 
F 
F 
F 
F 
F 
F 
s.d. 
NS 
MC 
MC 
MC 
LP 
LP 
NS 
NS 
MC 
MC 
MC 
I A 
I A 
I A 
I A 
IL A 
IIIA 
II A 
IIIA 
II A 
IIIA 
ILA 
I H-S-N-M-
I H-S-N-M-
I H-S-N-M-
N.DÍEOKTC 
im-s-N-M-
IIH-S-N-M-
IIH-S-N-M-
IIH-S-N-M-
IIH-S-N-M-
IIH-S-N-M-
N.D.EORTC 
47.6 
51.5 
48.8 
86.3 
54.0 
47.0 
40.8 
63.6 
60.4 
58.1 
62.6 
56.4+12. 
25 
10 
11 
9 
4 
3 
31 
12 
15 
16 
49 
.2)17 
3300 
3900 
-
2880 
3900 
3300 
4350 
3930 
3900 
4500 
4500 
3846 
7.5 
3.4 
6.1 
5.7 
4.3 
5.8 
5.0 
5.1 
4.2 
7.3 
5.0 
5.4 
5.6 
6.5 
8.0 
5.2 
7.9 
6.0 
9.8 
14.3 
4.6 
6.7 
8.5 
7.6 
1.3 
1.4 
2.2 
1.0 
2.1 
1.5 
1.4 
2.0 
1.6 
1.9 
1.9 
1.7 
> difference not significant (t= 0.32; df= 10.7; p= 0.75) 
Controls mean + s.d. 55.2+ 4.9* 
* L.P.: lymphocyte predominance3 N.S.: nodular sclerosing , U.C.: mixed cellularity}L.D.: lymphocyte depletion. 
** C.S.: clinical staging, P.S.: pathological staging. 
t A : without signs of generalization; B: with signs of generalization. 
t t H+ or ¡1- liver positive or negative; S+ or S- for spleen positive or negative; N+ or N- for lymph node positive 
or negative; M+ or M- for bone marrow positive or negative. 
φ U.Ό. : not done 
Table 2. Sunmary of fetients' Data and Results of VJiole aonplement level Pesay, E.S.R., Fibrinogen ¿rrount, a, 
Globulin Level, Leukocyte and Lymphocyte Count in Patients with Stages IIIA and IVA (group 2) 
Patients Age Sex Histo-
logy 
Staging 
CS PS 
Canplement E.S.R. Fibrinogen a^-Globulin Leukocytes Lymphocytes 
U/ml mm mg/l g/1 xl09/l xl09/l 
1 hr 
1. A.K.-T. 
2. W.D. 
3. M.U. 
4. G.B.-M. 
5. E.L. 
6. A.S. 
7. H.V. 
8. D.R. 
35 
17 
49 
26 
60 
17 
14 
26 
F 
M 
M 
F 
M 
F 
F 
F 
NS 
LP 
IP 
NS 
LD 
NS 
NS 
MC 
II A ІІШ-S-fN-M- 64.8 
UIA IIIH-S-N+M- 177.4 
UIA IHH-S+N-M- 81.5 
UIA IIIH-S-N-tM- 70.0 
UIA IIIH-S-N+M- 67.0 
IIIA IIIH-S+N+M- 73.4 
IV AL-^N.D. 
IV ADÍ*N.D. 
69.7 
102.4 
22 
5 
103 
70 
32 
45 
41 
24 
8190 
4275 
7050 
5700 
4950 
3200 
9.3 
5.5 
9.6 
8.1 
7.4 
7.2 
6.1 
8.7 
6.7 
5.9 
8.9 
7.8 
4.4 
10.9 
11.7 
6.7 
1.7 
2.0 
1.4 
1.6 
1.3 
1.3 
3.0 
1.2 
Patients mean + s.d. 
Controls mean + s.d. (ITFSO) 
43 5560 7.7 7.9 1.7 
difference significant (t=2.46;df=70;p= 0.043) 
* L+ : for lung positive 
сэ 
н- ** D+ : for (derma) skin positive 
Kabat and Mayer (9). All assays were carried out by the same 
technician. The "between-run" precision of the method has a s.d. 
of 0.528. The "between-day" precision has a s.d. of 4.30 5 (one 
way analysis of variance , random effect model) . Pooled serum from 
100 healthy donors from the Blood Transfusion Service, stored in 
ampoules at -70 С was used as internal standard. The results were 
corrected by a factor calculated from the internal standard. Our 
laboratory normal mean value + s.d. was 55.2 + 4.9 U/ml; n= 50). 
ESR was done according to Westergren (normal value males: 0-15 mm, 
females: 0-20 mm in 1 hour). 
Fibrinogen was determined according to Clauss (10) and Vermylen et al. 
(11) (normal value: 1400-4600 mg/1). 
The total serum protein was measured by a standard biuret reac­
tion, according to the principles of Weichselbaum (12) and the 
α-,-globulin content was determined by cellutose acetate electro­
phoresis according to the principles of Kohn (13,17), quantified 
by transmission densitometry (normal value: 3.6-8g/l). 
The leukocyte counts were performed with a Coulter Counter (model 
ZB) . 
The lymphocyte count was calculated from the total leukocyte and 
g 
differential counts and expressed as cell number xlO /1. Two 
hundred cells were differentiated after staining with May-Grûn-
wald's stain. Duplicate and triplicate lymphocyte counts were 
made to determine the mean lymphocyte count for individual pa-
tients . 
In agreement with Orfanakis (15), we considered the normal range 
g 
of leukocytes in peripheral blood between 4.3 and 10.0 xlO /1 for 
g 
lymphocytes between 1.5 and 4.0 xlO /1. 
Statistics 
Statistical analysis was performed with the two samples t-test 
of Welch for comparing the mean complement levels, leukocyte and 
lymphocyte count, between different groups and controls. 
One way analysis of variance was carried out to examine whether 
the means of the biological values were related to histological 
type and staging. 
Using a SPSS (Statistical Package for the Social Sciences) com-
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Table 3. Suranary of I^tients' Data and Results of Whole Carplement Level Assay, E.S.R., Fibrinogen Amount, a_-
Globulin Level, Leukocyte and Lynçhocyte Count in Patients with Stages IB and IIB (group 3) 
Patients Age Sex Histo- Staging Ccnplement E.S.R. Fibrinogen a2-Globulin Leukocytes Lymphocytes 
logy CS PS U/ml mm mg/1 g/1 xl09/l xl09/l 
1 hr 
1. B.H.-
2. E.M. 
3. A.L. 
4. E.R. 
5. W.P. 
6. J.D. 
7. J.T. 
8. D.V.-
9. W.T.-
-u. 
-s. 
-s. 
10. J.â.B. 
11. J.S.· 
12. N.S. 
-L. 
28 
38 
20 
33 
22 
17 
35 
35 
47 
26 
31 
31 
F 
M 
F 
F 
M 
F 
M 
F 
F 
F 
F 
F 
LP 
ID 
NS 
NS 
NS 
NS 
NS 
NS 
MC 
MC 
MC 
LD 
I В 
I В 
IIB 
IIB 
IIB 
IIB 
IIB 
IIB 
IIB 
IIB 
IIB 
IIB 
I H-S-N-M-
I H-S-N-M-
im-s-N-M-
IIH-S-N-M-
im-s-N-M-
IIH-S-N-M-
IIH-S-N-M-
N.D.EORTC 
IIH-S-N-M-
im-s-N-M-
N.D.EORTC 
IIH-S-N-M-
61.3 
67.8 
75.2 
64.8 
92.2 
94.1 
89.9 
83.4 
62.6 
102.7 
88.5 
98.7 
10 
42 
65 
22 
82 
143 
85 
115 
61 
40 
80 
80 
-
6000 
5775 
-
6600 
9900 
8190 
5100 
6725 
6000 
8970 
-
4.6 
6.5 
5.7 
9.3 
2.3 
14.4 
8.2 
8.7 
5.1 
8.1 
10.4 
8.3 
9.9 
5.4 
8.8 
13.1 
8.3 
11.5 
24.2 
9.4 
7.3 
13.5 
9.0 
9.4 
1.6 
1.8 
0.7 
1.8 
1.2 
3.0 
4.7 
1.2 
1.9 
2.3 
1.2 
2.7 
Patients mean + s.d. 81.7+14.8) 69 7028 7.6 10.8 2.0 
\ difference highly significant (t=6.15;df=l].6;p <0.0001) 
Controls mean + s.d. (n=50) 55.2+ 4.9 ) 
puter program stepwise discriminant analysis was performed to dis-
criminate with the aid of biological signs between the different 
groups. Where different specifications were possible (with respect 
to stopping criteria, inclusion levels etc.) the default values 
of the SPSS program were chosen. 
For testing the correlation between complement level, E.S.R. and 
fibrinogen level,Pearson's correlation coefficient was employed. 
RESULTS 
The mean whole complement level 56.4 U/ml in patients in group 1 
(stages IA and IIA) did not significantly (p=0.75) differ from 
the complement level in the control group (55.2 U/ml). One patient 
in this group with an increased complement level will be discussed 
below. 
The mean whole complement levels in patients in group 2 (iagesIIIA/ 
IVA): 88.3 U/ml, group 3 (stages IB/IIB): 81.7 U/ml, group 4 
(stages IIIB/IVB): 84.2 U/ml were significantly increased with 
respect to the control group: 55.2 U/mï (respectively p= 0.043, 
ρ <0'.0001, ρ <0.00001). The mean complement level of group 2,3 
and 4 together (84.3 U/ml) was also highly significant increased 
(p=0.00001) in comparison with group 1 and with the control group. 
The ESR was increased in 3 out of 11 patients with stage ΙΑ/ΙΙΑ.Ιη 
patients with stage IIIA and IVA, there was only 1 out of 8 pa­
tients with a normal ESR. All but one patient with В symptoms had 
an increased ESR. 
The fibrinogen level was normal in patients with stage IA and IIA, 
increased in 4 patients out of б patients with stage IIIA/IVA and 
in all 24 patients with general symptoms. 
All patients with stage IA/IIA, had normal oij-globulin serum con­
centrations. Four out of 8 patients with stage IIIA/IVA, 7 out of 
12 patients with stage IB/IIB and 9 out of 12 patients with stage 
IIIB/IVB had an increased a?-globulin concentration. 
Only 1 patient out of 11 with stage IA/IIA, 2 patients out of 8 
with stage IIIA/IVA and 4 out of 12 with stage IB/IIB had an increased 
leukocyte count, whereas 7 out of 12 patients with stage IIIB/IVB 
had leukocytosis. Moreover, in the last group 3 patients showed 
a leukopenia. There was no significant difference between the mean 
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Table 4. Sunmary of I^tients' Eata and Besults of Whole Сomplernent Level Assay, E.S.R., Fibrinogen ATOOunt, α--
Globulin Level, Leukocyte and Lynphocyte Count in Patients with Stages HIB and IVB (group 4) 
Patients Age Sex Histo- Staging Complement E.S.R. Fibrinogen «--Globulin Leukocytes Lymphocytes 
logy CS PS U/ml nun mg/l g/1 xl09/l xl09/l 
1 hr 
1. M.D.-P. 
2. P.G.-B. 
3. R.B. 
4. A.W. 
5. E.d.S. 
6. G.D. 
7. A.S. 
8. M.G. 
9. M.D.-H. 
10. J.B. 
11. P.v.D. 
12. R.A. 
48 
40 
18 
34 
20 
27 
28 
22 
51 
26 
37 
26 
F 
F 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
MC 
MC 
MC 
MC 
LD 
ИЗ 
NS 
NS 
MC 
MC 
MC 
LD 
HIB 
HIB 
HIB 
HIB 
HIB 
HIB 
IV Б 
IV в 
IV в 
IV в 
IV в 
г в 
iim-s-N-n*-
IIIH-S-N+M-
IHH-S+N-M-
IIIH-S-HU-M-
IIIH-S-W-tM-
N.D. 
N.D. 
N.D. 
IV H+S-W+M-
IV H+S+N+M-
IV H+S+N-H4-
N.D. 
83.R 
89.6 
76.2 
70.0 
102.0 
75.2 
103.9 
77.4 
69.8 
105.8 
84.8 
71.4 
85 
74 
90 
50 
146 
74 
54 
103 
92 
73 
77 
62 
5805 
9900 
7200 
5550 
10200 
6450 
7320 
6000 
8400 
6000 
-
6960 
8.4 
8.5 
6.1 
7.6 
10.1 
9.1 
7.0 
11.7 
8.1 
11.9 
9.0 
14.4 
20.4 
11.3 
12.2 
3.3 
4.2 
7.3 
15.5 
15.1 
16.5 
4.2 
15.1 
9.3 
2.1 
2.4 
2.6 
1.1 
1.3 
1.7 
2.3 
1.5 
2.2 
0.9 
4.6 
0.9 
Patients mean + s.d. 84.2+13.4\ 82 7253 9.3 11.2 2.0 
\ difference highly significant (t=7.38;df=11.7;p<0.00001) 
Controls mean + s.d. (n=50) 55.2+ 4.9) 
leukocyte count among all the four patient - groups. 
Less than normal lymphocyte counts were found in 4 out of 11 pa­
tients with stage IA/IIA, 4 out of 8 with stage IIIA/IVA and 4 out 
of 12 with stage IB/IIB and 4 out of 12 with IIIB/IVB. The differ­
ence between the mean lymphocyte count of the patient-groups was 
not significant. 
One way analysis of variance was applied to test whether the mean 
biological values were related to histological type and staging. 
It appeared that there was no relation to histology, however, a 
highly significant relation was found between the 4 different groups 
and the mean value of complement level, E.S.R., fibrinogen- and 
a„-globulin levels (p <0.005). 
According to the stepwise discriminant analysis only complement 
level, E.S.R. and fibrinogen values were related to the results 
of staging procedures. The other biological signs (i^-globulin, 
leukocyte- and lymphocyte count) were excluded,giving no essential 
contribution to these criteria. With complement level, E.S.R. and 
fibrinogen values it was possible to make a distinction between 
patients in group 1 (stagesIA and IIA) and the remaining groups 
(the more extensive forms stagesIIIA/IVA, as well as patients with 
symptoms of generalization IB/IIB and IIIB/IVB). It was however, 
not possible with these three biological signs to discriminate 
between each of the four groups separately. Applying the data of 
this method on all the patient material it was possible to locate 
accurately all patients in group 1 (stagesIA/IIA). Only one patient 
(3,6%) in the more extensive stage was unaccurately placed in the 
earlier stage. 
The correlation between complement, E.S.R. and fibrinogen for all 
the patient material was as follows: complement-Ε.S.R. : r=0.30 
(p=0.052), complement-fibrinogen:r= 0.31 (p=0.063), and E.S.R.-
fibrinogen: r= 0.75 (p <10 ). This indicates a moderate corre­
lation between complement and E.S.R. and complement and fibrinogen, 
and a very strong correlation between E.S.R. and fibrinogen. 
When correlations were studied between complement, E.S.R. and fibrin­
ogen for every patient group, then no correlation at all was found 
between complement and E.S.R. and complement and fibrinogen. The 
correlation between E.S.R. and fibrinogen was again significant 
(r=0.46,· p= 0.005) . 
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DISCUSSION 
A very strong relation was found between increased whole comple-
ment level and symptoms of generalization and more extensive forms 
of this disease (stages III and IV) without signs of generalization. 
In our material only one patient in stage IA demonstrated an in -
creased complement level. This is patient number 4 J.D. who probably 
was understaged. His spleen scan showed splenomegaly, although 
clinically it was not palpable. Unfortunately possible splenic 
localization could not be confirmed or excluded because laparoto-
my was not performed (according to the randomization protocol). 
In the excellent review of Ruddy et al.(16) about complement, they 
show, that the weight of the available evidence points to the 
macrophage as the cellular source of most complement proteins. The 
only exception being the hemolytically active Cl macromolecule, 
which has been recognized in intestinal epithelium. Therefore the 
increase in complement Içvel is rrobably the expression of a high 
activity of the reticulo-endothelial system, as a consequence of 
the presence of the tumor. 
The E.S.R. is a highly nonspecific indicator of disease activity. 
It is often elevated in patients with previously untreated Hodgkin's 
disease (17), and such elevation in the series reported by West-
ling (18) were correlated significantly with a decreased survival 
time. Tubiana (19) found no correlation between E.S.R. and clinical 
stage but a strong correlation with loss of weight, fever and ab-
sence or presence of systemic symptoms. E.S.R. had a significant 
prognostic value, especially for patients without systemic symp-
toms. Unfortunately, the majority of patients studied by Tubiana 
were already under treatment. In our group of patients an increase 
of E.S.R. is mainly found in the more advanced or aggressive forms 
of Hodgkin's disease. Its relation with staging is not as good as 
that of complement. As Tubiana we found a strong relation to the 
absence or presence of systemic symptoms. 
Fibrinogen is also a nonspecific indicator of disease activity. 
Croizat and Creyssel (20) showed fibrinogen levels above 5 g/1 in 
60% of 100 patients. In our series all patients with systemic symn-
toms had an increased level. 
a2~Globulin is often increased in Hodgkin's disease (77% of cases) 
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(21). The increase of a^-globulin is largely due to an increase of 
haptoglobulin and ceruloplasmin (22) . There is no correlation 
with disease activity. 
It has been claimed that leukocytosis of significant degree is an 
unfavourable prognostic sign, associated with the more extended 
forms. Paradoxically, there is also evidence that leukopenia car­
ries similar connotation (17). Most cases of an increased leuko­
cyte count in our series were found in the more advanced stages 
HIB and IVB. However, there was no significant difference between 
this and the other groups. We did not find any correlation be­
tween leukocytopenia and staging. 
There was no significant difference in the lymphocyte counts 
between the different stages. This is in agreement with studies 
from Heier (23), Kaplan (17), Tubiana (19), but not from Brown 
(24) and Young (25). They found a significant lower count in pa­
tients with stage III and IV, than in those with stage I and II. 
From the results of our study it is evident that the best initial 
parameters which correlates well with disease activity are whole 
complement level, E.S.R. and fibrinogen level. None of the 3 pa­
rameters per se is superior. However, because of the poor corre­
lation between whole complement level and E.S.R. and complement 
level and fibrinogen on the one hand, and the high correlation 
between E.S.R. and fibrinogen on the other hand, it may be concluded 
that measuring of complement level gives a completely differ­
ent information than the two other parameters. This could be of 
interest in the initial staging, because it gives another parameter 
for differentiating between favourable and unfavourable forms of 
Hodgkin's disease. 
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ABSTRACT 
Serum immunoglobulin levels IgG, IgA and IgM have been investiga-
ted in 51 untreated patients with Hodgkin's disease and 10 2 con-
trol persons. In the patients with Hodgkin's disease the mean IgG 
and IgA level was significantly raised (p: 0.0001 for both). The 
mean IgM level in males was normal, in females also significantly 
increased (p: 0.0012). The increase in IgA level was the most pro-
nounced among the three immunoglobulins. 
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INTRODUCTION 
The studies of Dubin in 1947 (1), and later of Schier et al.(2) 
in 1956 of the delayed hypersensitivity reaction in patients with 
Hodgkin's disease have ushered extensive research of the immunologi-
cal status of Hodgkin's patients. The initial general conclusion 
that patients with Hodgkin's disease have an impaired cell-mediated 
immunity (2-10) is recently modified. The earlier studies were 
conducted on treated patients and it became clear that radiotherapy 
and chemotherapy have a depressant influence on immunity (9,11-13). 
Recent studies on newly admitted untreated patients showed that 
an impairment of skintest reactivity and lymphocyte function exists, 
but that this deficiency is a quantitative, rather than a qualita-
tive one (14-16) . 
The only study to our knowledge in Hodgkin's patients regarding 
immunoglobulin levels (17), as indicators of the humoral immunologi-
cal status, revealed a reduced IgM level in 24 out of 50 cases. 
The IgA levels also tended to be low; the IgG levels were normal 
or raised. This study was carried out in treated patients and had 
therefore to be reevaluated. 
In this paper IgG, IgA and IgM levels in untreated patients with 
Hodgkin's disease are presented and correlated with staging and 
histology. 
MATERIAL AND METHODS 
Patients 
Fifty-one consecutive, new and untreated Hodgkin's patients were 
examined. Twenty-four were males and twenty-seven females;their 
mean age was 30 years (range 14 to 60 years, median 28 years). 
None of the patients had concomitant overt infectious disease. The 
histologic classification used, was that of the Rye Conference (18). 
Patients were classified in 4 stages according to the Ann Arbor 
Conference (19). Exploratory laparotomy was performed in 39 pa-
tients. Six patients with stage IV disease and one patient with 
stage HIB were only classified on clinical grounds, because of 
the severity of their illness. Five patients were not submitted 
to explorative laparotomy, because of commitment to the EORTC-
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Table 1. Sumnary of Patients' Data and Serum ІгтяшодІоЬиІіп Levels (rog/ml) 
Patient Sex Age Histologic Clinical Pathologic Serum immunoglobulins 
type* staging staging** IgG IgA IgM 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
M.L.-S. 
G.L.-H. 
H.B. 
A.H. 
J.D. 
B.H.-U. 
E.M. 
J.V.O. 
J.L.-S. 
M.L.-H. 
J.V. 
A.H.-H. 
J.V. 
M.B.-M. 
M.R.-J. 
M.E.-G.E. 
J.S. 
A.L. 
E.R. 
W.P. 
J.T. 
D.V.-S. 
W.T.-S. 
J.d.B. 
J.S.-L. 
N.S. 
J.D. 
R.D. 
M.L. 
W.D. 
F 
F 
M 
M 
M 
F 
M 
M 
F 
F 
M 
F 
F 
F 
F 
F 
M 
F 
F 
M 
M 
F 
F 
F 
F 
F 
F 
M 
F 
M 
35 
26 
47 
26 
19 
28 
38 
43 
32 
21 
36 
43 
20 
26 
24 
39 
29 
20 
33 
22 
35 
35 
47 
26 
31 
31 
17 
18 
17 
17 
NS 
MC 
MC 
MC 
MC 
LP 
ID 
LP 
NS 
NS 
NS 
MC 
LP 
NS 
MC 
NS 
LP 
NS 
NS 
NS 
NS 
NS 
MC 
MC 
MC 
ID 
NS 
MC 
LD 
LP 
I 
I 
I 
I 
I 
I 
I 
II 
II 
II 
II 
II 
III 
III 
III 
III 
II 
II 
II 
II 
II 
II 
II 
II 
II 
II 
III 
III 
A 
A 
A 
A 
A 
В 
в 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
Β 
Β 
Β 
Β 
Β 
Β 
Β 
Β 
Β 
Β 
Β 
Н Т В 
III 
Α 
I H-S-N-M-
I H-S-N-M-
I H-S-N-M-
I H-S-N-M-
N.Dí**EOKrC 
I H-S-N-M-
I H-S-N-M-
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
N.D. EORTC 
N.D. ЕОКГС 
II H-S-N-M-
l!r H-S-N-M-
II H-S-N-tt-
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
N.D. EORTC 
II H-S-N-M-
II H-S-N-M-
N.D. EORTC 
II H-S-N-M-
II H-S-N-M-
II H-S-N-M-
IIJ-S-N-M-
IIIH-S-N4M-
11.0 
12.4 
10.4 
9.7 
11.9 
14.7 
16.4 
8.4 
13.7 
15.7 
12.1 
14.6 
10.8 
16.7 
15.1 
14.4 
15.7 
12.8 
16.9 
8.7 
27.9 
11.2 
18.1 
17.7 
19.1 
14.1 
15.1 
12.7 
12.1 
8.8 
2.22 
2.18 
2.68 
1.57 
2.03 
2.37 
4.59 
4.67 
2.45 
1.84 
2.88 
2.08 
2.95 
3.52 
2.68 
3.10 
2.58 
2.24 
4.47 
2.68 
5.60 
1.88 
1.91 
4.13 
4.90 
2.68 
3.46 
3.44 
3.66 
1.47 
3.75 
2.03 
1.41 
1.95 
0.86 
2.07 
2.18 
5.43 
1.76 
2.23 
1.01 
1.09 
1.72 
1.70 
2.71 
0.80 
1.79 
2.26 
1.92 
0.69 
1.92 
1.48 
4.15 
3.03 
2.39 
0.86 
1.72 
1.08 
3.12 
0.78 
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Table 1. Surrmary of Patients' Data and Serum Iimunoglobulin Levels (nig/ml) 
continued 
Patient Sex Age Histologic Clinical Pathologic Serum imnunoglobulins 
type* staging staging** IgG IgA IgM 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
46. 
47. 
48. 
49. 
50. 
51. 
E.L. 
A.K.-T. 
M.U. 
A.S. 
A.K. 
P.G.-B. 
M.D.-P. 
R.v.d.B. 
A.v.W. 
E.V.d.S. 
G.D. 
H.V. 
D.R. 
M.D.-H. 
P.v.D. 
J.B. 
G.H. 
M.G. 
A.S. 
R.A. 
J.J. 
M 
F 
M 
F 
M 
F 
F 
F 
M 
M 
M 
F 
F 
F 
M 
M 
M 
M 
M 
M 
M 
60 
35 
49 
17 
32 
40 
48 
18 
34 
20 
27 
14 
26 
51 
37 
26 
26 
22 
29 
26 
38 
Ш 
NS 
LP 
NS 
NS 
MC 
MC 
fC 
MC 
in 
LD 
NS 
NS/MC 
MC 
MC 
MC 
MC 
NS 
NS 
ш 
NS/LD 
III 
II 
III 
III 
III 
III 
III 
III 
III 
III 
III 
A 
A 
A 
A 
A 
В 
В 
в 
в 
в 
в 
^ 
^1>НА 
IV 
IV 
IV 
IV 
в 
в 
в 
в 
™u-
B 
ν 
^ 
^Lf 8 
IIIH-S-N+M-
IIIH-S-tfJ-M-
IIIH-S+N-M-
IIIH-S+N+M-
IIIH-S+N+M-
IIIH-N-N4M-
IIIH-S-№M-
iim-s+N-M-
IIIH-S4N-M-
IIIH-S+N+M-
N.D. 
N.D. 
N.D. 
TV H+S+N+M-
IV H+S+N+M-
IV H+S+N+M-
IV ΗΗ£+Ν+Μ-
N.D. 
N.D. 
N.D. 
N.D. 
11.0 
14.4 
11.4 
15.3 
15.7 
16.7 
11.0 
13.7 
15.7 
7.4 
14.4 
19.8 
8.7 
24.7 
15.1 
9.4 
13.5 
11.2 
13.9 
17.1 
15.3 
3.10 
3.05 
2.91 
4.01 
4.67 
5.89 
4.98 
3.44 
3.98 
1.93 
3.86 
5.79 
2.22 
5.84 
6.92 
0.92 
2.84 
3.66 
2.29 
2.69 
6.20 
1.64 
2.11 
1.02 
1.56 
2.18 
1.18 
1.09 
2.71 
0.94 
0.70 
1.01 
1.40 
2.18 
1.64 
1.09 
0.70 
1.40 
1.20 
2.81 
2.03 
2.96 
* L.P.: lymphocyte predominance, N.S.: nodular sclerosing, M.C.: mixed cellularity, 
L.D.: lymphocyte depletion. 
** H+ or H- for liver positive or negative; S+ or S- for spleen positive or negative; 
11+ or N- for lymph node positive or negative; M+ or M- for marrow positive or 
negative. 
L+ for lung positive; D+ for (derma) skin positive; E: extranodal. 
***N.D.: not done. 
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trial which requires a randomization between laparotomy and no 
laparotomy in clinical stages I and II. When laparotomy was per-
formed, patients were classified according to pathologic stage, 
otherwise on clinical criteria. Patients' data are summarized in 
Table 1. 
10 2 healthy donors from the Blood Transfusion Service served as 
normal controls (their mean age was 32 years, median 32 years, 
range 17 to 6 2 years). 
Methods 
Blood was collected by venipuncture before staging-laparotomy was 
done. The samples were taken between 8.30 and 10.30 a.m. After 30 
minutes the clotted blood was centrifugea. The serum was decanted 
and stored at -70oC. Quantitative estimations of IgG, IgN and IgA 
in serum were performed with an automated turbidimetric immunopre-
cipitation method (20) and expressed in mg/ml. 
During the period of examination the same serum standard was used. 
This standard was prepared by mixing serum from 40 healthy adults 
and stored after freeze drying in ampoules at -25 C. This refer-
ence standard had previously been calibrated against a highly 
purified polyclonal IgG, IgA and IgM preparation. 
RESULTS 
In 40 patients the serum IgG level was normal and was increased 
in 11 as shown in Table 2 and Fig 1. The mean was significantly 
(p=0.0001) higher than the mean of the controls. Although the 
number of patients is too small for reliable statistical analysis, 
the data obtained in this study (Fig. 1) suggest, that the mean 
of serum IgG globulin levels in patients with signs of generali-
zation (B symptoms) was higher than in patients without signs of 
generalization (A symptoms). 
The IgA level was in the normal range in 29 patients and increased 
in 22. The rise of IgA was much more pronounced than IgG. The mean 
of IgA was very significantly (p= 0.0001) increased in Hodgkin's 
patients compared with the controls. 
The mean IgM level in males was normal, in females significantly 
(p=0.0012) increased. There were 5 male and 9 female Hodgkin's 
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Table 2. Serum immunoglobulin L e v e l s in P a t i e n t s and Controls 
en 
IgG mg/ml 
mean + s.d. 
controls males 10.9+2.5 (n=44) 
fanales 11.2+2.6a(n=58) 6.0-16.4 
total 11.1+2.6 (n=102) 5.9-16.3 
range IgA mg/ml 
mean + 2s.d. mean + s.d. 
5.9-15.9 2.06+0.64(n=46) 
,b. 
range IgM mg/ml 
mean + 2s.d. mean + s.d. 
0.78-3.34 1.24-Ю.44 (n=40) 
1.98+0.74"η=52) 0.50-3.46 
2.02+0.69 (n=98) 0.64-3.40 
1.47+0.36 (=n55) 
range 
mean + 2s.d. 
0.36-2.12 
0.57-2.19 
Hodgkin's nales 
disease fanales 
14.0+3.8 (π=51) 3.34+1.371η=5]) 
1.62+1.04 (η=24) 
2.02+0.82 4 (r^27) 
Significance of difference between males and females in the controls 
(Mann and Whitney U-test of Wilcoxon's two samples test): 
a: p= 0.43 b: p= 0.55 c : p= 0.007 
Significance of difference between Hodgkin's patients and controls. 
1: p - 0.0001 2: p= 0.0001 2: p= 0.2502 4: p= 0.0012 
patients with an IgM level above the accepted upper limit of 
normal for our population. No patient had an IgM level below the 
lower limit of normal. 
The mean immunoglobulin levels in Hodgkin's patients according to 
histologic type are given in Table 3. 
Table 3. Serum Immunoglobulin Levels in Controls and in Patients 
with Hodgkin's Disease according to Histologic Type 
No of 
patients 
M F 
4 2 
6 12 
8 11 
6 2 
Histologic 
type 
L.P. 
N.S. 
M.C. 
L.D. 
IgG 
mg/ml 
+ s.d. 
11.6 + 3.0 
14.8 + 4.0 
14.2 + 4.0 
13.5 + 3.2 
IgA 
mg/ml 
+ s.d. 
2.83 + 1.05 
3.32 i 1.20 
3.40 + 1.66 
3.59 + 1.34 
IgM 
mg/ml 
+ s.d, 
M 
2.29 + 2.14 
1.64 + 0.80 
1.20 + 0.38 
1.72 + 0.81 
F 
1.90 
1.89 + 0.71 
2.23 + 0.91 
1.89 
controls 11.1 + 2.6* 2.02 t 0.69** 1.24 + 0.44*** 1.47 + 0.36**** 
(*nFl02) (** n=98) (*** n=40) (**** n=55) 
It appeared that patients with Hodgkin's disease lymphocytic predom-
inance have almost normal immunoglobulin levels. It is to be not-
ed, that this subgroup consists of the smallest number of pa-
tients. The raised mean IgM level in males in this histologic sub-
type is due to the enormous rise of IgM level in one single pa-
tient (J.V.O.: IgM: 5.43 mg/ml). There were no significant differ-
ences in mean immunoglobulin levels between the four histologic 
subgroups. 
DISCUSSION 
In agreement with Goldman (17) we found in patients with Hodgkin's 
disease a normal or increased IgG level. However, contrary to 
Goldman results, it was found in this study that the mean IgA level 
in Hodgkin's patients was significantly higher than in the controls. 
No patient had a decreased IgA level. In addition it appeared that 
the mean IgM level in male Hodgkin's patients was normal, and sig-
nificantly increased in females. No patient had an IgM level below 
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Fig.l. Serum Immunoglobulins in Patients with Hodgkin's Disease according to Stage 
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the lower limit of normal. This is in disagreement with the find-
ings of Goldman. 
Comparing immunoglobulin levels between different groups of per-
sons is difficult. Serum immunoglobulin concentrations show a great 
range between individual persons (21-23) , but are rather constant 
in the course of time for any individual person (24-26). All immu-
noglobulins show a rise in the second decade to reach at that time 
adult levels (27-29). In adults the serum IgG and IgA levels gradu-
ally, increase slightly according to the study of Kalff (21) but 
is constant according to Buckley and Dorsey (30). Kalff found no 
change in IgM level in elderly persons, Buckley and coworker ob-
served, however, a fall in advancing age. The patients in this 
study were mostly young adults, and the ages were comparable with 
those of the controls. An alteration due to age is therefore un-
likely. 
According to literature (26,31-33) there exist no differences in 
IgA and IgG lévete between males and females. IgM levels however, 
are higher in females than in males (21,26,31-33). We found also 
in the control group a significant higher IgM level in females 
than in males, and no difference in IgA and IgG levels. Goldman 
(17) does not mention the sex either in Hodgkin's patients, nor 
in the controls. The decrease in IgM level which he found, could 
possibly be explained by a special male/female ratio. 
The tendency of rise of all the three immunoglobulins could be 
caused by a generalized hyperactivity of the reticulo-endotheli-
al-system as found in certain chronic infections. 
The increase in IgA level is the most pronounced from the three 
immunoglobulins and points possibly to another explanation. The 
increase of IgA is not necessarily concomitant with a rise of 
IgG and IgM. In the 22 patients witn an increased IgA, 9 had IgG 
levels and 8 IgM levels above normal. Raised IgA levels are found 
in other kinds of neoplastic diseases: breastcancer (34), hepato-
cellular carcinoma (35), cancers of the lung, mouth and gut (32) . 
It is suggested by Hughes (32) , that this raised IgA level in 
patients with cancers associated with secreting mucous membranes 
is due to infection of the mucosa. 
The decreased IgA level found by Goldman (17) could be explained 
by the fact that the patients studied were almost all treated 
100 
patients. 
No significant differences in immunoglobulin levels between the 
four histological forms of Hodgkin's disease were found. 
Acknowledgements 
The authors gratefully acknowledge Mrs. H.Holtman and Miss M.Man-
tingh for their technical assistance. They are indebted to 
Mr. Ph. van Eiteren, M Sc for his statistical analysis. 
101 
REFERENCES 
1.Dubin,Ι.Ν.: The poverty of the immunological mechanism in pa­
tients with Hodgkin's disease. Ann.Int.Med. 27:898, 19 47. 
2.Schier,W.W., Roth,Α., Ostroff,G. and Schrift,M.H.: Hodgkin's 
disease and immunity. Am.J.Med. 20:94, 1956. 
3.Aisenberg,А.С.: Immunologic status of Hodgkin's disease. Canaer 
19: 385, 1966. 
4.Chase,M.W.: Delayed-type hypersensitivity and the immunology of 
Hodgkin's disease, with a parallel examination of sarcoidosis. 
Cancer Res. 26: 1097, 1966. 
5. Aisenberg,АГ.: Studies on delayed hypersensitivity in Hodgkin's 
disease. J.Clin.Invest. 41: 1964, 1962. 
6.Sokal,J.E. and Primikirios,N. : The delayed skin test response 
in Hodgkin's disease and lymphosarcoma: effect of disease activ­
ity Canaer 14: 597, 1961. 
7.Kelly,W.D., Lamb,D.L·., Varco,R.L. and Good,R.Α.: An investiga­
tion of Hodgkin's disease with respect to the problem of homotrans-
plantation. Ann.Ν.Ϊ.Aoad.Sai. 87: 187, 1960. 
8.Kelly,W.W., Good,R.A. and Varco,R.L.:Anergy and skin homograft 
survival in Hodgkin's disease. Surg.Gyneo.Obstet. 107: 565, 1958. 
9 HanJ1. and Sokal,J.E.: Lymphocyte response to phytohemagglutinin 
in Hodgkin's disease. Am.J.Med. 48: 728, 1970. 
10.Hersh,E.M. and Oppenheim,J.J.: Impaired in vitro lymphocyte 
transformation in Hodgkin's disease. N.E.J.M. 273: 1006,1965. 
11.Schwartz,R.S.: Are immunosuppressive anticancer drugs self-
defeating? Cancer Res. 28: 1452, 1968. 
12.Braeman,J. and Deeley,T.J.: Radiotherapy and the immune response 
in cancer of the lung. Brith.J.Radiology 46: 446, 1973. 
13.Check,J.H., Damsker,J.I., Brady,L.W. and O'Neill,E.A.: Effect 
of radiation therapy on mumps-delayed type hypersensitivity reac­
tion in lymphoma and carcinoma patients. Canaer 32: 580,19 73. 
14.Young,R.C., Corder,M.P., Berard,C.W. and DeVita,V.T.: Immune 
alterations in Hodgkin's disease: effect of delayed hypersensitiv­
ity and lymphocyte transformation on course and survival. Arch. 
Int.lied. 131: 446, 1973. 
IS.Eltringham,J.R. and Kaplan,H.S.: Impaired delayed hypersensi­
tivity responses in 154 patients with untreated Hodgkin's dis-
102 
ease. Natl.Cancer Inst.Monogr.36·. 107, 1973. 
16.Levy,R. and Kaplan,H.S.: IrapaiiEd lymphocyte function in untreat­
ed Hodgkin's disease. N.E.J.M. 290: 181,1974. 
17.Goldman,J.M. and Hobbs,J.R.: The immunoglobulins in Hodgkin's 
disease. Immunology 13: 421, 1967. 
18.Lukes,R.J., Graver,L.F., Hall,Т.С, Rappaport,H. and Rubin,P.: 
Report of the nomenclature committee. Cancer Res. 26: 1311, 1966. 
19.Carbone,P.P., Kaplan.H.S., Musshoff,К., Smithers,D.W. and Tu-
biana,M.: Report of the committee on Hodgkin's disease staging 
classification. Cancer Res. 31: 1860, 1971. 
20.Munster,van P. and Hoelen,G.: An automated turbidimetric immu-
noprecipitation method for serum proteins. Submitted for publi­
cation. 
21.Kalff,M.W.: Genetic and environmental influences on serum im­
munoglobulin levels iñ man. Thesis 1969, Leiden. 
22.Fudenberg,H.H., Heremans,J.F. and Franklin,E.С.: A hypothesis 
for the genetic control of synthesis of the gamma globulins. Ann. 
Inst.Pasteur 104: 155, 1963. 
23.Allansmith,M., McClellan,B and Butterworth,M.: The influence 
of heredity and environment on human immunoglobulin levels. J. 
Immunol. 102: 1504, 1969. 
24.Allansmith,M., McClellan,B. and Butterworth,Μ.: Stability of 
human immunoglobulin levels. Proc.Soo.exp.Biol 125: 404, 1967. 
25.Mondorf,W. and Kollmar,M.: Das quantitatieve Verhalten von IgG, 
IgA und IgM, sowie des Transferrins, Ceruloplasmins, α -Antitryp­
sins und des β.Α-Globulins bei Normalpersonen im Verlaufe von 5 
Monate. Klin.Wsckr. 47: 1055, 1969. 
26.Nadorp,J.H.S.M.: Immuunglobuline A en immuunglobuline A defi­
ciëntie. Thesis 1975. Nijmegen. 
27.Stiehmf E.R. and Fudenberg,H.H.: Serum levels of immune glob-
ulins in health and disease. A survey. Pediatrics 37: 715, 1966. 
28.Allansmith,M., McClellan,B., Butterworth,M. and Malloney,J.R.: 
The development of immunoglobulin levels in man. J.Pediatric. 72: 
276, 1968. 
29.Stoop,J.W., Negers,В.J.Μ., Sanders,P.С. and Ballieux,R.E.: 
Serum immunoglobulin levels in healthy children and adults. Clin. 
exp.Immunol. 4: 101, 1969. 
30.Buckley,C.E. and Dorsey,F.C.: Serum immunoglobulin levels 
103 
throughout the life-span of healthy man. Ann. Int.Med. 75: 673, 
1971. 
31.Butterworth,M., McClellan ,B. and Allansmith,M.: Influence of 
sex on immunoglobulin levels. Nature 214: 1224, 1967. 
32.Hughes,N.R.: Serum concentrationsof IgG, IgA and IgM immunoglob­
ulins in patients with carcinoma, melanoma and sarcoma. J.Natl. 
Cancer Inst. 46: 1015, 1971. 
33.Johansson,S.G., Hogman,C.F. and Killander,J.: Quantitative immu­
noglobulin determination. Acta Path. Microbiol. Scand. 74: 519, 
1968. 
34.Roberts,Μ.Μ., Bathgate,Ε.M. and Stevenson,A.: Serum immunoglob­
ulin levels in patients with breast cancer. Cancer 36: 221,1975. 
35.Akdamer,K., Epps,A.C., Maumus,L.T. and Sparks,R.D.: Immunoglcb-
ulin changes in liver disease. Ann.N.Y.Acad. Sci. 197: 101, 1972. 
104 
Chapter Vili 
SUMMARY 
Chapter I presents a review of literature about the value of lapa­
rotomy and splenectomy as a routine staging procedure in Hodgkin's 
disease. The principal advantage of this procedure is the possi­
bility of accurate assessment of Involvement of the spleen. From 
the published data the accuracy of the clinical evaluation of spleen 
involvement is only 65%. 
Other advantages include supplementary information on the state of 
abdominal lymph nodes, liver and bone marrow. 
Splenectomy improves hematopoietic tolerance to aggressive radio­
therapy and chemotherapy. 
Chapter II outlines the studies performed and their specific ob­
jectives in this thesis, namely the influence of splenectomy on im­
munity. Mention is made of the correlation of whole complement lev­
els and immunoglobulin concentrations and staging. 
In chapter III and IV the results of the influence of splenectomy 
on the eellular -immunologia status in patients with Hodgkin's dis­
ease are reported. In chapter III the influence of splenectomy on 
the in-vitro lymphocyte response to phytohemagglutinin and poke-
weed mitogen is given. Chapter IV reports the effect of splenectomy 
on skintest reactivity, the number of lymphocytes, the proportion 
of Ε-and EAC-binding lymphocytes and on the in-vitro lymphocyte 
response to PHA, allogeneic lymphocytes and a cocktail of antigens. 
It is concluded, that about 10 days after splenectomy, there is 
no demonstrable untoward effect on the cellular immunological po­
tency. 
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T/wo striking findings in this study were the significant increase 
in PHA stimulation of peripheral lymphocytes postoperative in sta­
ges III and IV, and a significant decrease in Ε-binding lymphocytes 
in patients with splenic weight of 240 g and more. 
Chapter V is devoted to the effect of splenectomy on humoral immu­
ni. ty. The humoral immune profile investigated is the antibody-for­
ming capacity as measured by immunoglobulin levels, isohemagglu-
tinin titres, antistreptolysin titres, E.coli antibody titres and 
complement levels. 
After splenectomy a highly significant drop in IgG level was found 
in Hodgkin's patients stagesl and II. 
The IgM concentration diminished slightly in stagesl and II, and sig­
nificantly in stagesIII and IV. In the control surgery group, how­
ever, a significant rise in IgM level was found. 
The E.coli antibody titre increased after the operation in Hodgkin's 
as well as in the control surgery group, but the rise in the con­
trol surgery group was significantly higher. 
The whole complement level increased significantly in Hodgkin's 
and control surgery patients. The data are discussed from the point 
of view of the possible increased infection rate after splenecto­
my in general, and in Hodgkin's disease in particular. 
In Chapter VI the whole serum complement level and other biological 
signs in 43 untreated Hodgkin's patients are described and are 
correlated with staging. 
A highly significant increase of the mean whole complement level 
was found in stages IIIA and IVA and in all stages with systemic 
symptoms. 
The best initial parameters which correlated well with disease 
activity were whole complement level, E.S.R. and fibrinogen level. 
It is concluded, that whole complement level can give additional 
information and could be of help in differentiating between favour­
able and unfavourable forms of Hodgkin's disease. 
Chapter VII gives the immunoglobulin levels in 51 untreated pa­
tients with Hodgkin's disease. 
The mean IgA and IgG level was found to be significantly above 
normal. The mean IgM level was normal in male Hodgkin's patients, 
but significantly raised in female patients. The findings concer­
ning IgA and IgM levels are contrary to a previously published 
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study in which the authors reported that IgA and IgM levels tended 
to be low. This contradiction is probably due to the fact that 
the patients reported in literature were nearly all treated. 
In conclusion it was found, that about 10 days after splenectomy 
there was no untoward effect on the cellular immunological status. 
The humoral immunity seemed to be impaired. 
Whole complement level could be important in discriminating between 
favourable and unfavourable forms of Hodgkin's disease. 
The mean immunoglobulin values IgG and IgA were high in patients 
with Hodgkin's disease. IgM level was increased only in female 
Hodgkin's patients. 
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STELLINGEN 
1 
Bij patiënten met de ziekte van Hodgkin is de cellulaire immuni-
teit ongeveer tien dagen na de exploratieve laparotomie met sple-
nectomie niet verminderd ten opzichte van voor de operatie. 
Dit proefschrift. 
2 
De phytohemagglutininestimulatie als methode ter vaststelling van 
het percentage T-lymfocyten is onbetrouwbaar. 
Dit proefschrift. 
3 
De "incubatietijd" bij de ziekte van Hodgkin is waarschijnlijk 
korter dan 6 maanden in tegenstelling tot wat in de literatuur 
wordt vermeld. 
D.J.Th.Wagener, C.Haanen. 
Lancet ii, 747 (1975) . 
4 
De bimodaliteit in de leeftijdsverdeling van patiënten met de 
ziekte van Hodgkin toont grote overeenkomst met die van virale 
aandoeningen (verkoudheid en influenza). 
D.J.Th.Wagener. 
Lancet i, 880 (1974). 
5 
Bestralingssynovectomie van een gewricht door middel van isotopen 
dient overwogen te worden bij hemofiliepatienten met een recidi-
verende hemarthros, voor dat er röntgenologische afwijkingen aan-
toonbaar zijn. 
A.Ahlberg in Handbook of Hemophilia. Excerpta 
Medica, Amsterdam 1975. 
6 
Bij algemeen intern onderzoek van vrouwen boven de 50 jaar dient 
mammografie te geschieden. 
Interimrapport Werkgroep Bevolkingsonderzoek 
Mammacarcinoom, Nijmegen. 
7 
Stervensbegeleiding is in de eerste plaats een taak voor familie-
leden en vrienden en niet voor professionele hulpverleners. 
8 
Computerised tomography (CT scanning) is de grootste aanwinst in 
de diagnostiek van anatomische structuren sinds de ontwikkeling 
van het klinisch röntgenonderzoek. 
9 
Bij de behandeling van patiënten met mamma-carcinoom dient men 
rekening te houden met het feit dat reeds in een groot percentage 
metastasering heeft plaats gevonden voor dat de tumor klinisch 
waarneembaar is. 
M.Tubiana, P.Chauvel, A.Renaud, E.P.Malaise. 
Bulletin du Cancer 62, 341 (1975). 
10 
Het universitaire schaap met de 5 poten: klinisch werkzaam weten-
schappelijk medewerker (Dr J.L.J.Jansen, proefschrift 1975) kan 
zich evenwichtig voortbewegen, omdat de onderwijspoot lam is aan-
gelegd. 
11 
Bij belangrijke voetbalwedstrijden dient de scheidsrechter niet 
alleen te worden bijgestaan door grensrechters, maar ook door een 
videoteam. 
Nijmegen, 7 mei 1976. D.J.Th. Wagener 



